Immune system disorder
MONDO:0005046A disorder resulting from an abnormality in the immune system.
Also known as: disease of immune system, disease or disorder of immune system, disorder of immune system, immune disease, immune disorder, immune dysfunction, immune system disease or disorder, immune system disorder
12340 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 1572 trials in this tab.
-
Can a single gene therapy turn the body into a Cancer-Fighting factory?
⭐️ CURE ⭐️ Not yet recruitingThis phase 1 trial is testing a new gene therapy called UB-VV500 for people with multiple myeloma that has returned or stopped responding to treatment. The therapy works by giving the body genetic instructions to produce its own CAR T cells that target two proteins on myeloma cel…
Phase: PHASE1 • Sponsor: Umoja Biopharma • Aim: ⭐️ CURE ⭐️
Last updated Aug 18, 2026 02:00 UTC
-
Can a single shot build a cancer army inside the body?
⭐️ CURE ⭐️ Not yet recruitingThis trial tests an experimental gene therapy called UB-VV400, designed to instruct a person's own cells to become CAR T cells that target CD22 on B-cell cancers. It is given together with rapamycin, a drug that may help the therapy work better. The study enrolls adults with rela…
Phase: PHASE1, PHASE2 • Sponsor: Umoja Biopharma • Aim: ⭐️ CURE ⭐️
Last updated Aug 18, 2026 02:00 UTC
-
Can a new drug combo make stem cell transplants safer for frail AML patients?
⭐️ CURE ⭐️ Not yet recruitingThis trial is testing whether a new conditioning regimen, called VABu, can improve outcomes for adults with acute myeloid leukemia (AML) who are in first remission but are too frail for standard transplant prep. The regimen combines venetoclax, azacitidine (or decitabine), and bu…
Phase: NA • Sponsor: The First Affiliated Hospital of Soochow University • Aim: ⭐️ CURE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
Can a One-Time infusion of Dual-Target CAR-T cells outsmart resistant blood cancers?
⭐️ CURE ⭐️ Not yet recruitingThis phase 1 trial is testing an experimental therapy called CD19/CD20 dual-target in vivo CAR-T for people with relapsed or refractory B-cell malignancies—blood cancers that have not responded to standard treatments. The approach uses a lentiviral product to engineer a patient's…
Phase: PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: ⭐️ CURE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat myeloma
⭐️ CURE ⭐️ Not yet recruitingThis trial is testing an experimental therapy called CT0596, which uses a patient's own immune cells that are engineered to recognize and attack multiple myeloma cells. The study includes adults with relapsed or refractory multiple myeloma who have already tried at least three pr…
Phase: PHASE1, PHASE2 • Sponsor: UCARsgen Biotech Limited • Aim: ⭐️ CURE ⭐️
Last updated Aug 14, 2026 00:00 UTC
-
Engineered donor cells could outsmart relapsed myeloma
⭐️ CURE ⭐️ Not yet recruitingThis trial tests whether a specially engineered donor stem cell transplant, called Orca-Q, can safely treat people with high-risk multiple myeloma that has returned or not responded to prior therapy. The transplant uses donor blood-forming cells and immune cells, with certain T c…
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: ⭐️ CURE ⭐️
Last updated Aug 14, 2026 00:00 UTC
-
Can a new drug combo reset the immune system to beat relapsed leukemia?
⭐️ CURE ⭐️ Not yet recruitingThis trial tests whether a combination of sonrotoclax, cladribine, and cytarabine, followed by a stem cell transplant, can improve survival in adults with relapsed or refractory acute myeloid leukemia (AML). Participants receive the chemotherapy regimen, then undergo an allogenei…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Can engineered immune cells outsmart resistant blood cancers?
⭐️ CURE ⭐️ Not yet recruitingThis early-stage trial is investigating whether a new type of CAR T-cell therapy, which targets a protein called BAFFR on cancer cells, can safely and effectively treat adults with B-cell acute lymphoblastic leukemia or B-cell lymphoblastic lymphoma that has returned or not respo…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Can a pill and injection combo beat AML without harsh chemo?
⭐️ CURE ⭐️ Not yet recruitingThis trial tests a combination of two drugs, azacitidine and venetoclax, as the first treatment for young, fit adults (ages 18-50) with newly diagnosed acute myeloid leukemia (AML). The goal is to see how many patients achieve complete remission after one or two cycles of this th…
Phase: PHASE2 • Sponsor: Pakistan Blood and Marrow Transplant (PBMT) Group • Aim: ⭐️ CURE ⭐️
Last updated Aug 07, 2026 00:00 UTC
-
Can a poison become a cure? arsenic trioxide put to the test in blood cancer transplant
⭐️ CURE ⭐️ Not yet recruitingThis early-phase trial tests whether adding arsenic trioxide to a standard stem cell transplant can prevent the cancer from coming back in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study enrolls about 20 patients whose cancers have …
Phase: PHASE1 • Sponsor: University of Michigan Rogel Cancer Center • Aim: ⭐️ CURE ⭐️
Last updated Aug 01, 2026 00:00 UTC
-
One-shot CAR-T therapy takes on stem cell transplant for multiple myeloma
⭐️ CURE ⭐️ Not yet recruitingThis phase 3 trial tests whether a single infusion of AZD0120, a CAR-T cell therapy that targets two proteins on myeloma cells, can outperform the standard approach of high-dose chemotherapy followed by a stem cell transplant. The study enrolls adults newly diagnosed with multipl…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: ⭐️ CURE ⭐️
Last updated Aug 01, 2026 00:00 UTC
-
Can a liposomal chemo combo outsmart tough leukemias?
⭐️ CURE ⭐️ Not yet recruitingThis phase 3 trial compares two drug combinations for adults with a high-risk form of myelodysplastic syndrome (MDS-IB2) or newly diagnosed acute myeloid leukemia (AML) that is either secondary to prior treatment or occurs in older age. One group receives a standard regimen of az…
Phase: PHASE3 • Sponsor: Ruijin Hospital • Aim: ⭐️ CURE ⭐️
Last updated Jul 31, 2026 00:00 UTC
-
Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
⭐️ CURE ⭐️ Not yet recruitingThis phase 2 trial is testing whether a single infusion of a patient's own genetically modified immune cells, called C-CAR168, can safely and effectively treat lupus nephritis that has not responded to standard therapies. The cells are designed to target and eliminate specific im…
Phase: PHASE2 • Sponsor: AbelZeta Inc. • Aim: ⭐️ CURE ⭐️
Last updated Jul 30, 2026 00:00 UTC
-
Can a smart immune cell with a kill switch beat tough lymphomas?
⭐️ CURE ⭐️ Not yet recruitingThis Phase 1 trial tests a new type of cell therapy for people with relapsed or refractory CD30-positive lymphomas, including Hodgkin lymphoma and certain non-Hodgkin lymphomas. The treatment uses a patient's own immune cells that are genetically engineered to recognize and attac…
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: ⭐️ CURE ⭐️
Last updated Jul 29, 2026 00:00 UTC
-
Can a single infusion of engineered immune cells beat back hard-to-treat multiple myeloma?
⭐️ CURE ⭐️ Not yet recruitingThis early-stage trial is testing an experimental therapy called KIV-318 for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. KIV-318 is a type of CAR-T cell therapy that reprograms a patient's own immune cells to recognize …
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: ⭐️ CURE ⭐️
Last updated Jul 26, 2026 00:00 UTC
-
Can a fourth drug tip the scales against an aggressive leukemia?
⭐️ CURE ⭐️ Not yet recruitingThis trial is testing whether adding venetoclax to standard intensive chemotherapy plus midostaurin can improve outcomes for adults with a type of acute myeloid leukemia that has a FLT3 mutation. The study enrolls people aged 18 to 70 with newly diagnosed disease who are healthy …
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: ⭐️ CURE ⭐️
Last updated Jul 26, 2026 00:00 UTC
-
Could bone marrow from deceased donors cure blood cancers?
⭐️ CURE ⭐️ Not yet recruitingThis study tests whether bone marrow from deceased donors can be used to treat people with blood cancers like leukemia and lymphoma. Participants receive a transplant of cryopreserved marrow from a deceased donor or standard cells from a living donor. The goal is to see if the de…
Phase: NA • Sponsor: Ossium Health, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Jul 22, 2026 00:00 UTC
-
Ultra-Fast CAR-T cells aim to beat back tough lymphomas
⭐️ CURE ⭐️ Not yet recruitingThis phase 2 trial tests whether a new CAR-T cell therapy called UF-KURE19 can effectively treat adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The therapy is made from a patient's…
Phase: PHASE2 • Sponsor: Kure Cells, INC • Aim: ⭐️ CURE ⭐️
Last updated Jul 22, 2026 00:00 UTC
-
RNA vaccine aims to control HIV without daily pills
⭐️ VACCINE ⭐️ Not yet recruitingThis study tests an experimental RNA-based vaccine called BNT168 in adults both with and without HIV. The goal is to see if the vaccine is safe, triggers an immune response, and can help control the amount of virus in the body. Participants receive either the vaccine or a placebo…
Phase: PHASE1 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 15, 2026 00:00 UTC
-
Can a common drug boost Chemo's power against Hard-to-Treat leukemia?
Disease control Not yet recruitingThis trial is testing whether adding hydroxyurea to a standard chemotherapy combination can improve outcomes for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The study is conducted in two parts: first to find the safest dose of hydroxy…
Phase: PHASE1, PHASE2 • Sponsor: Christer C Nilsson • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New pill combo aims to tame tough leukemia
Disease control Not yet recruitingThis study tests an oral chemotherapy drug, cladribine, combined with two other drugs (low-dose cytarabine and venetoclax) in people with acute myeloid leukemia (AML). The first part finds the safest dose; the second part checks if that dose helps control the disease. About 58 ad…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Could a 7-Day antibiotic course replace 3 weeks for silent STI?
Disease control Not yet recruitingThis trial tests whether a 7-day course of doxycycline can effectively cure asymptomatic anal lymphogranuloma venereum (LGV), a sexually transmitted infection caused by Chlamydia trachomatis. Currently, treatment lasts 21 days, but recent studies suggest a shorter course may work…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Can a new injection calm severe eczema in kids?
Disease control Not yet recruitingThis trial is testing an experimental drug called 611 in children aged 2 to 12 with moderate-to-severe atopic dermatitis, a common skin condition that causes itchy, inflamed skin. The drug is designed to block a specific immune signal that drives the inflammation behind eczema. T…
Phase: PHASE3 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
A spoonful of milk a day: could it rewire Kids' allergies?
Disease control Not yet recruitingThis trial tests whether giving children with cow's milk allergy tiny, increasing amounts of milk each day can help them tolerate it. Infants aged 6 to 18 months with a confirmed allergy will be randomly assigned to receive oral immunotherapy for 1-1.5 years or to avoid milk as u…
Phase: NA • Sponsor: Laura Ozer Kettner • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Can a targeted biologic outperform standard care for a rare blistering disease?
Disease control Not yet recruitingThis trial compares two treatment approaches for moderate to severe pemphigus vulgaris, a rare autoimmune disease causing painful blisters on skin and mucous membranes. One group receives rituximab (a biologic that targets immune B-cells) plus corticosteroids, while the other get…
Phase: EARLY_PHASE1 • Sponsor: Khyber Teaching Hospital • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Experimental cell therapy takes on tough leukemia
Disease control Not yet recruitingThis early-phase trial tests a new treatment called TSLPR-CART for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified in a lab to target a protein called TSLPR found on …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Could a painless microneedle pad ease Raynaud's in scleroderma?
Disease control Not yet recruitingThis Phase 3 trial is testing whether a microneedle pad delivering botulinum toxin A can improve symptoms of Raynaud's phenomenon and digital ulcers in people with systemic sclerosis. The study compares the microneedle treatment to a placebo, measuring changes in finger temperatu…
Phase: PHASE3 • Sponsor: Khon Kaen University • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Can a new injection plus a pill tame ulcerative colitis?
Disease control Not yet recruitingThis early trial is testing whether a new investigational drug called HX15001, given as an injection, can be safely combined with an existing pill (etrasimod) to treat moderate-to-severe ulcerative colitis. The study will include about 32 adults with the condition and will focus …
Phase: PHASE1 • Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Can a new pill tame ulcerative colitis Flare-Ups?
Disease control Not yet recruitingThis clinical trial is testing an experimental oral medication called AC-101 in adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease. The study aims to see if AC-101 can help achieve clinical remission—meaning fewer symptoms and …
Phase: PHASE2 • Sponsor: Accro Bioscience (Suzhou) Limited • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
A handful of peanuts a day might keep stress at bay
Disease control Not yet recruitingThis trial investigates whether eating a daily serving of peanuts can reduce stress and improve markers of heart health in adults who report high stress levels. Participants will eat either peanuts or a calorie-matched snack for a period, while researchers measure changes in stre…
Phase: NA • Sponsor: USDA, Western Human Nutrition Research Center • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
A pill that could outsmart food allergies? trial tests remibrutinib
Disease control Not yet recruitingThis Phase 3 study is testing whether an oral drug called remibrutinib can help people with IgE-mediated allergies to peanuts, cow's milk, or hen's egg tolerate larger amounts of the allergen without symptoms. Adults and adolescents aged 12 to 65 will receive either the drug or a…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Supercharged immune cells take on tough T-Cell cancers
Disease control Not yet recruitingThis Phase 2 trial tests a new treatment for aggressive T-cell blood cancers. Patients receive specially engineered natural killer (NK) cells from donated cord blood, along with chemotherapy, to try to keep the cancer in remission. The study will enroll 70 adults aged 18-80 whose…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
Can a hormone mimic curb the need for bloodletting in a blood cancer?
Disease control Not yet recruitingThis trial tests whether rusfertide, a synthetic version of the hormone hepcidin, can help people with polycythemia vera—a condition where the bone marrow makes too many red blood cells—by lowering iron availability and keeping red blood cell counts in check. The study enrolls Ch…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New cell therapy B019 takes on tough lymphoma in first human trial
Disease control Not yet recruitingThis early-stage trial tests a new cell therapy called B019 in 48 people with relapsed or refractory B-cell non-Hodgkin's lymphoma. The main goals are to check safety and find the right dose. Researchers will also look for early signs that the treatment shrinks tumors.
Phase: PHASE1 • Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?
Disease control Not yet recruitingThis phase 3 trial is testing whether a radioactive drug called iopofosine I 131 can keep Waldenstrom macroglobulinemia (a rare blood cancer) from getting worse for longer than the standard combination of rituximab, cyclophosphamide, and dexamethasone (R-CD). The study enrolls ab…
Phase: PHASE3 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a pill clear psoriasis on hands and feet?
Disease control Not yet recruitingThis trial tests whether an oral medication called zasocitinib (TAK-279) can reduce the redness, thickening, scaling, and painful cracks of palmoplantar psoriasis, a type of psoriasis that affects the palms and soles. Adults with moderate-to-severe non-pustular palmoplantar psori…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
Disease control Not yet recruitingThis phase 2 trial is testing whether combining two immunotherapy drugs—vilastobart and retifanlimab—can shrink tumors in people with metastatic pancreatic cancer that has a BRCA1, BRCA2, or PALB2 gene mutation. Participants receive both drugs by IV infusion over several months. …
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo shows promise for aggressive lymphoma
Disease control Not yet recruitingThis phase 2 trial tests whether adding the drug epcoritamab to standard chemotherapy (DA-EPOCH-R) helps people with high-risk Burkitt lymphoma. About 43 adults will receive the combination. The study will check how many complete at least three cycles of treatment and track overa…
Phase: PHASE2 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug aims to tame autoimmune hepatitis and cut steroid use
Disease control Not yet recruitingThis study tests a drug called inebilizumab in 180 adults with autoimmune hepatitis, a condition where the immune system attacks the liver. The goal is to see if the drug can reduce liver inflammation and allow patients to take lower doses of steroids. Participants will receive e…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a Triple-Action antibody deepen remissions in myeloma?
Disease control Not yet recruitingThis phase II trial is testing whether a new investigational drug called IBI3003, when combined with an existing anti-CD38 antibody (daratumumab), can improve outcomes for people with multiple myeloma. The study includes patients with relapsed or refractory disease, as well as ne…
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Engineered yeast pill takes on superbug c. diff in first human trial
Disease control Not yet recruitingThis early-stage trial tests an oral capsule containing a genetically modified probiotic yeast designed to neutralize toxins produced by C. diff bacteria. The study first evaluates safety in healthy adults, then in people at risk for recurrent C. diff infection. Participants take…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
A shot at safer CAR t: early brain protection for lymphoma patients?
Disease control Not yet recruitingThis trial tests whether giving anti-inflammatory drugs directly into the spinal fluid at the first sign of a brain-related side effect can stop it from becoming severe. The study enrolls adults with non-Hodgkin lymphoma who are receiving CD19 CAR T cell therapy, a treatment that…
Phase: PHASE2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can an immune booster outsmart brain lymphoma?
Disease control Not yet recruitingThis trial is testing whether adding an immunotherapy drug called penpulimab to a standard chemotherapy regimen can help people with primary central nervous system lymphoma, a rare type of brain cancer. Participants, who have not yet received treatment, are randomly assigned to r…
Phase: NA • Sponsor: WEI XU • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a blood pressure pill slow MS disability?
Disease control Not yet recruitingThis phase 2 trial tests whether indapamide, a common diuretic, can slow the worsening of walking ability in people with progressive multiple sclerosis (MS). Participants take one tablet daily for 12 months, with walking speed measured regularly. The study aims to see if the drug…
Phase: PHASE2 • Sponsor: Eva M.M. Strijbis • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a Once-Weekly pill clear stubborn psoriasis?
Disease control Not yet recruitingThis phase 2 trial is testing whether an experimental oral drug called HS-20118 can improve moderate to severe plaque psoriasis, a condition that causes thick, scaly patches on the skin. About 120 adults with the condition will receive either HS-20118 or a placebo once a week for…
Phase: PHASE2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new injection calm severe eczema when creams fall short?
Disease control Not yet recruitingThis study tests whether an investigational drug called tilrekimig, given as injections alongside medicated creams or ointments, can improve moderate-to-severe eczema (atopic dermatitis) in people aged 12 and older. Participants will be randomly assigned to receive either tilreki…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new shoulder implant restore arm function where others fail?
Disease control Not yet recruitingThis study is following people who receive a Tornier Perform™ Reversed MonoPost shoulder replacement to see how well it works and how safe it is. The implant is designed for patients with severe shoulder damage, such as from arthritis, fractures, or failed previous surgeries. Res…
Sponsor: Stryker Trauma and Extremities • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new biologic calm severe eczema?
Disease control Not yet recruitingThis clinical trial is testing whether the drug nemolizumab can help treat moderate-to-severe atopic dermatitis (a common type of eczema) in Chinese patients aged 12 and older. Participants will receive either nemolizumab or a placebo (a look-alike with no active drug) every four…
Phase: PHASE3 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for HIV patients with aggressive lymphoma: early trial launches
Disease control Not yet recruitingThis early-phase trial will test the safety and feasibility of adding the experimental drug glofitamab to standard chemoimmunotherapy (R-CHOP) in 15 people newly diagnosed with HIV-associated large B-cell lymphoma. Glofitamab is a bispecific antibody that helps the immune system …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
A spoonful of nuts? trial tests Multi-Allergy desensitization in kids
Disease control Not yet recruitingThis trial tests whether giving children with allergies to multiple nuts a daily oral immunotherapy—a mix of peanut, cashew, walnut, hazelnut, and almond proteins—can help them tolerate these foods. Children aged 1-12 with confirmed allergies to at least two of these nuts are ran…
Phase: NA • Sponsor: Medical University of Warsaw • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can umbilical cord blood keep leukemia at bay in older patients?
Disease control Not yet recruitingThis phase 3 trial is testing whether adding an umbilical cord blood infusion to standard consolidation chemotherapy can help older adults with intermediate- or high-risk acute myeloid leukemia (AML) stay free of relapse. About 132 patients aged 60 to 80 who achieved remission af…
Phase: PHASE3 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New shot aims to stop hidden leukemia in its tracks
Disease control Not yet recruitingThis study tests whether a drug called blinatumomab, given as a simple injection under the skin, can control small amounts of leftover leukemia cells (called measurable residual disease, or MRD) in adults with B-cell acute lymphoblastic leukemia. The goal is to prevent the cancer…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a new pill tame inflammatory bowel disease? early safety trial begins
Disease control Not yet recruitingThis Phase 1 trial is testing an experimental oral drug called QLS1510, which is being developed for inflammatory bowel disease (IBD). The study enrolls healthy adults aged 18 to 45 to evaluate the drug's safety, tolerability, how it moves through the body, and the effect of food…
Phase: PHASE1 • Sponsor: Shanghai Qilu Pharmaceutical Research and Development Center LTD • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Leukemia combo shot and pill shows promise in early trial
Disease control Not yet recruitingThis Phase 2 trial tests a combination of two drugs—blinatumomab (given as a shot under the skin) and olverembatinib (a pill)—in 60 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The goal is to see if this combo can control the disease safely. Pa…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could cutting salt after childbirth tame dangerous blood pressure?
Disease control Not yet recruitingThis trial tests whether a low-sodium diet can improve blood pressure control in people who had a hypertensive disorder of pregnancy. Participants receive either a provided diet with less than 2000 mg of sodium per day or a standard diet with no salt restrictions for the first we…
Phase: NA • Sponsor: Women and Infants Hospital of Rhode Island • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can gut bacteria help rebuild immunity after stem cell transplants?
Disease control Not yet recruitingThis trial explores whether transplanting gut bacteria from healthy donors can help restore the immune system in people who have weak immunity after a stem cell transplant. The study first observes immune recovery in patients to identify those with severe deficiency, then gives a…
Phase: PHASE1, PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new drug calm the Gut's overactive immune response in Crohn's?
Disease control Not yet recruitingThis phase 2 trial is testing whether an investigational drug called SL-325 can help adults with moderate to severe Crohn's disease. The study will compare SL-325 against a placebo to see if it reduces gut inflammation and improves symptoms. Participants will receive the treatmen…
Phase: PHASE2 • Sponsor: Shattuck Labs, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new pill tame ulcerative colitis?
Disease control Not yet recruitingThis early-stage trial is testing an experimental oral medication called HRS-7085 in adults with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. The main goal is to see if the drug is safe and tolerable, and to understand how it moves through the body…
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new injection calm Sjogren's nerve damage?
Disease control Not yet recruitingThis trial tests whether an experimental drug called efgartigimod can reduce nerve damage and pain in adults with Sjogren's disease. Participants will receive either the drug or a placebo as a subcutaneous injection. The study measures changes in neuropathy symptoms and quality o…
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New CAR-T therapy aims to calm overactive immune system in muscle weakness disease
Disease control Not yet recruitingThis early study tests a new treatment called HN2301 in 6 adults with generalized myasthenia gravis, a disease that causes muscle weakness. The treatment uses the body's own immune cells to target and reduce harmful immune activity. The main goal is to check safety and see how we…
Phase: PHASE1 • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a Two-Drug combo keep aggressive lymphoma at bay?
Disease control Not yet recruitingThis trial is testing whether a combination of pomalidomide (a pill) and rituximab (an infusion) can help young adults with high-risk diffuse large B-cell lymphoma (DLBCL) stay in remission after their first round of treatment. Participants, who must be under 60 and have responde…
Phase: PHASE4 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a single injection reprogram immune cells to tame lupus and scleroderma?
Disease control Not yet recruitingThis early study tests a new drug called HN2302, which aims to create CAR-T cells inside the body to target and control autoimmune diseases like lupus and scleroderma. The trial will enroll 12 adults to check safety and see if the treatment works. It is a first step, so results w…
Phase: PHASE1 • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for stubborn Graft-Versus-Host disease: experimental drug combo enters early trial
Disease control Not yet recruitingThis early-phase study tests whether the drug sarilumab can safely help adults with chronic graft-versus-host disease (cGVHD) that did not improve with the standard drug belumosudil. Ten participants will receive sarilumab alone, and researchers will monitor side effects and drug…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new antibody tame lupus flares?
Disease control Not yet recruitingThis trial tests whether an experimental drug called ESG206 can safely reduce disease activity in adults with systemic lupus erythematosus (SLE). Participants will receive either ESG206 or a placebo, and researchers will measure how many achieve a meaningful improvement in lupus …
Phase: PHASE2 • Sponsor: Shanghai Escugen Biotechnology Co., Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New combo tackles tough leukemia
Disease control Not yet recruitingThis early-phase study tests two drugs, blinatumomab and revumenib, given together to adults with a rare and aggressive form of acute lymphoblastic leukemia (ALL) that has a specific genetic change called KMT2A rearrangement. The main goal is to find a safe dose and understand si…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new injection clear psoriasis when other biologics fail?
Disease control Not yet recruitingThis phase II trial is testing an investigational drug called SHR-1139 in adults with plaque psoriasis who have not responded well to at least one biologic treatment. Participants will receive either SHR-1139 or a placebo via subcutaneous injection over a 52-week treatment period…
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New combo therapy aims to treat leukemia without harsh chemo
Disease control Not yet recruitingThis study tests whether combining two drugs, inotuzumab and blinatumomab, is safe and effective for adults newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). The trial includes 26 people aged 18 and older who are either 55+ or cannot tolerate standard chemotherapy…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart resistant myeloma?
Disease control Not yet recruitingThis phase II trial is testing whether combining teclistamab, an antibody that helps immune cells attack myeloma cells, with pomalidomide, a drug that slows cancer growth, can control multiple myeloma in people whose disease has returned or stopped responding after 1-3 prior trea…
Phase: PHASE2 • Sponsor: Odense University Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a single injection tame severe asthma in fungal allergy?
Disease control Not yet recruitingThis study is testing whether tezepelumab, an injectable medication, can help people with severe asthma caused by allergic bronchopulmonary aspergillosis (ABPA), a condition where the immune system overreacts to certain fungi. The trial will enroll 10 adults aged 18 to 75 who hav…
Phase: NA • Sponsor: Qianfoshan Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a psychedelic help break meth addiction in people with HIV?
Disease control Not yet recruitingThis trial explores whether a single dose of psilocybin, combined with motivational support therapy, can help people with HIV who have moderate-to-severe methamphetamine use disorder reduce or stop their meth use. Participants will be randomly assigned to receive either a higher …
Phase: PHASE2 • Sponsor: Nicky Mehtani, MD, MPH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Spanish-language pump training aims to close diabetes tech gap for latino youth
Disease control Not yet recruitingThis trial tests whether a culturally tailored, Spanish-language onboarding and support program helps Latino youth aged 10–20 with type 1 diabetes adopt and consistently use the Medtronic MiniMed 780G automated insulin delivery system. Participants receive one-on-one nutrition su…
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can Open-Source insulin systems match commercial ones without meal announcements?
Disease control Not yet recruitingThis trial tests whether open-source automated insulin delivery (AID) systems can control blood sugar as well as commercial systems in adults with type 1 diabetes, even when meals are not announced. Participants will use both types of systems for four weeks each, with a focus on …
Phase: NA • Sponsor: Institut de Recherches Cliniques de Montreal • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can donor immune cells tame stem cell transplant risks?
Disease control Not yet recruitingThis trial tests whether an experimental cell therapy called agenT-797 is safe for people receiving a stem cell transplant for blood cancers like leukemia or myelodysplastic syndrome. Participants get an infusion of agenT-797 about a week after their transplant. The main goal is …
Phase: PHASE1 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a new injection tame ulcerative colitis?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called SHR-7590 to see if it is safe and tolerable when given by injection under the skin or into a vein. It involves healthy volunteers and people with moderate-to-severe ulcerative colitis, a condition that causes inflammat…
Phase: PHASE1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new pill outsmart Treatment-Resistant blood cancer?
Disease control Not yet recruitingThis phase III trial is testing whether an experimental drug called TQB3909 can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) whose disease has returned or stopped responding to prior treatments. Participants will be randomly assigned to re…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a diabetes drug curb chronic Pouch-Related bathroom trips?
Disease control Not yet recruitingThis trial tests whether tirzepatide (Zepbound) can reduce daily bowel frequency in adults with an ileal pouch-anal anastomosis (IPAA) who have chronic high bowel frequency despite standard anti-diarrheal therapy. Participants will be assigned to receive tirzepatide or standard c…
Phase: PHASE4 • Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for myeloma patients who relapse after CAR t: bispecific antibody trial launches
Disease control Not yet recruitingThis phase 2 trial tests a drug called linvoseltamab in 34 people with multiple myeloma whose cancer returned after BCMA CAR T-cell therapy. Linvoseltamab is a bispecific antibody that helps the immune system attack myeloma cells. The main goal is to see how many patients respond…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could a new Antibody-Lowering drug ease autoimmune brain inflammation?
Disease control Not yet recruitingThis Phase 2 trial tests efgartigimod PH20 SC, a drug that lowers harmful antibodies, in 170 adults and teens with autoimmune encephalitis (AIE). Participants receive either the drug or a placebo, and researchers measure changes in disability and symptoms over up to 3 years. The …
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can engineered immune cells tame multiple sclerosis?
Disease control Not yet recruitingThis trial tests an experimental therapy called SYS6020 for people with relapsing or progressive multiple sclerosis that hasn't responded well to standard treatments. SYS6020 uses a patient's own immune cells, engineered to target and potentially reduce harmful B cells involved i…
Phase: PHASE1, PHASE2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New trial aims to match diabetes drugs to patients for better heart and kidney protection
Disease control Not yet recruitingThis phase 2 trial will test two drugs, finerenone and sotagliflozin, in 57 people with type 1 diabetes who are at risk for heart and kidney problems. The goal is to see if matching the right drug to each person's specific diabetes subtype can improve early signs of heart and kid…
Phase: PHASE2 • Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for young adults with CML: asciminib under Real-World scrutiny
Disease control Not yet recruitingThis study looks at how well the drug asciminib works and how safe it is for young adults with chronic myeloid leukemia (CML) in the Gulf region. Researchers will collect information from medical records of about 80 people aged 18 and older who have taken asciminib. The main goal…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for tough myeloma: early trial of BP2202 begins
Disease control Not yet recruitingThis early-stage trial is testing a new drug called BP2202 in 24 people with multiple myeloma that has come back or no longer responds to standard treatments. The main goal is to see if BP2202 is safe and to find the best dose. Researchers will also watch for any signs that the d…
Phase: PHASE1 • Sponsor: BrightPath Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new injection match an existing eczema treatment?
Disease control Not yet recruitingThis trial is testing whether an experimental biologic called IBI3027 works as well as the approved drug dupilumab for people with moderate-to-severe atopic dermatitis (eczema). About 520 adults will be randomly assigned to receive either IBI3027 or dupilumab as a subcutaneous in…
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Triple-Drug combo outsmart resistant leukemia?
Disease control Not yet recruitingThis trial tests whether adding gilteritinib to the standard drugs azacitidine and venetoclax can help adults with a type of acute myeloid leukemia (AML) that has returned or stopped responding to prior treatment. Participants receive the three-drug combination in repeated 28-day…
Phase: PHASE2 • Sponsor: Florian Kuchenbauer • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New CAR t combo takes on Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase trial tests a new type of CAR T-cell therapy called FT836, given together with the drug daratumumab, in 12 adults with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the combination is safe…
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
Disease control Not yet recruitingThis phase III trial is testing whether regular antibody infusions (immunoglobulin replacement therapy) can prevent infections better than standard antibiotic prophylaxis in people who have received CAR-T cell therapy for B-cell acute lymphoblastic leukemia or B-cell lymphoma. CA…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
Disease control Not yet recruitingThis phase 2 trial is testing whether an oral drug called flonoltinib maleate can help adults with myelofibrosis, a rare bone marrow disorder that often causes an enlarged spleen and severe symptoms. The study compares three different daily doses (50 mg, 75 mg, and 100 mg) to see…
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new drug combo outperform standard care for a tough blood cancer?
Disease control Not yet recruitingThis trial is testing whether adding the drug venetoclax to different chemotherapy regimens can improve outcomes for people newly diagnosed with acute myeloid leukemia (AML). It compares three experimental combinations against the standard treatment in 320 patients aged 14 and ol…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a probiotic keep ulcerative colitis in check?
Disease control Not yet recruitingThis trial is testing whether a probiotic supplement called Colipral, which contains a specific strain of E. coli bacteria, can improve gut health in people with ulcerative colitis who are in remission but still have digestive issues. Participants will take either the supplement …
Phase: NA • Sponsor: University of Padova • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new antibody help lupus patients ditch steroids?
Disease control Not yet recruitingThis trial is testing whether anifrolumab, an experimental antibody, can help Chinese adults with moderate-to-severe systemic lupus erythematosus (SLE) achieve remission. Participants receive anifrolumab infusions over 52 weeks alongside standard care, with a focus on safely redu…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a biologic drug calm the gut in ulcerative colitis? a Real-World trial seeks answers
Disease control Not yet recruitingThis study is testing whether guselkumab, a biologic drug, can help people with moderate-to-severe ulcerative colitis achieve remission. Participants receive IV infusions followed by maintenance injections. The trial tracks clinical, endoscopic, and histological healing over 48 w…
Sponsor: Second Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a targeted antibody calm severe eczema?
Disease control Not yet recruitingThis first-in-human trial evaluates BYN-001, an antibody designed to block IL-25, a protein linked to atopic dermatitis (eczema). The study first tests the drug in healthy volunteers to assess safety and how it moves through the body, then in people with moderate to severe eczema…
Phase: PHASE1 • Sponsor: Bionyra Pharma • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Could a single injection tame lupus and Sjögren's?
Disease control Not yet recruitingThis early-stage trial is evaluating an investigational drug called QLS2404, given as an injection, to see if it is safe and tolerable. The study first tests single doses in healthy volunteers, then moves to multiple doses in people with systemic lupus erythematosus or primary Sj…
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new gel calm psoriasis Flare-Ups?
Disease control Not yet recruitingThis trial tests whether a topical gel called GM-XANTHO can reduce the severity of psoriasis, a chronic skin condition that causes red, scaly patches. About 65 adults with plaque psoriasis will apply the gel or a placebo daily for 28 days. Researchers will measure changes in skin…
Phase: PHASE2 • Sponsor: Xantho Biotechnology Co., LTD • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
A drug after transplant may stop scleroderma from coming back
Disease control Not yet recruitingThis pilot trial tests whether giving the immunosuppressant drug mycophenolate mofetil (MMF) for six months after a stem cell transplant can prevent systemic sclerosis from relapsing. Six adults with scleroderma who are undergoing a stem cell transplant will take MMF starting 90 …
Phase: PHASE2 • Sponsor: Ottawa Hospital Research Institute • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new pill tame ulcerative colitis when others fail?
Disease control Not yet recruitingThis trial is testing an experimental oral drug called PTT-621 in adults aged 18-70 with moderate-to-severe ulcerative colitis who haven't responded well to standard treatments. Participants will take PTT-621 tablets for 12 weeks. The main goal is to see if the drug can improve t…
Phase: PHASE2 • Sponsor: Pyrotech Therapeutics, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a Dual-Targeting antibody stop amyloid buildup in its tracks?
Disease control Not yet recruitingThis phase 2 trial is testing an investigational drug called QLS4131 in people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up in organs and cause damage. QLS4131 is a trispecific antibody designed to target and eliminate the plasma cells produci…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a targeted drug combo outsmart an aggressive lymphoma?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding the targeted drug pirtobrutinib to a standard chemotherapy regimen (Pola-R-CHP) can improve outcomes for people newly diagnosed with a specific, harder-to-treat subtype of diffuse large B-cell lymphoma (Non-GCB DLBCL). The study will e…
Phase: PHASE2 • Sponsor: Changzhou No.2 People's Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a targeted drug shrink Hard-to-Treat thymic tumors?
Disease control Not yet recruitingThis phase II trial is testing whether an experimental drug called sacituzumab tirumotecan (Sac-TMT) can shrink tumors in people with thymic carcinoma that cannot be surgically removed and has already been treated with platinum-based chemotherapy. Participants receive the drug in…
Phase: PHASE2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a 'Universal' cancer target outsmart resistant blood cancers?
Disease control Not yet recruitingThis early-phase trial is testing an experimental drug called VTRU200 in people with certain blood cancers that have returned or not responded to standard treatments, including acute myeloid leukemia, high-risk myelodysplastic syndromes, and diffuse large B-cell lymphoma after CA…
Phase: PHASE1, PHASE2 • Sponsor: Vitruviae • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could a new pill tame ulcerative colitis? a First-in-Human trial aims to find out
Disease control Not yet recruitingThis early-stage trial evaluates an investigational oral drug called ONO-6414 in healthy adults and in people with active ulcerative colitis. The main goals are to assess the drug's safety, tolerability, and how the body processes it. The study includes single and multiple doses,…
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new injection tame lupus when standard care fails?
Disease control Not yet recruitingThis early-phase trial is testing an investigational drug called ACG102, given by intravenous infusion, in people with refractory active systemic lupus erythematosus (SLE) — a form of lupus that has not responded well to standard treatments. The main goals are to check the drug's…
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a lower dose of a myeloma drug keep the disease in check with fewer side effects?
Disease control Not yet recruitingThis trial asks whether a reduced dose of belantamab mafodotin, combined with pomalidomide and dexamethasone, can control relapsed or refractory multiple myeloma as effectively as the standard dose while causing fewer side effects. Adults with this blood cancer who have had at le…
Phase: PHASE2 • Sponsor: Polish Myeloma Consortium • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a targeted drug boost standard chemo for aggressive lymphoma?
Disease control Not yet recruitingThis trial is testing whether adding pirtobrutinib, a targeted drug, to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific subtype of diffuse large B-cell lymphoma (non-GCB DLBCL). The study will enroll about 34 adults with newly diagnosed di…
Phase: PHASE2 • Sponsor: Changzhou No.2 People's Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Ready-Made immune cells take on blood cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new cell therapy called ALA-101 for people with CD19+ non-Hodgkin lymphoma or leukemia. The therapy uses donor immune cells that are specially designed to find and attack cancer cells. The main goals are to check safety and find the best dose, with …
Phase: PHASE1 • Sponsor: Arovella Therapeutics Ltd • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new injection tame relapsing MS?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called RO7845860, given as an injection under the skin, in people with relapsing multiple sclerosis (MS). The main goals are to check the drug's safety, how the body handles it, and its effects on immune cells. The study w…
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new pill tame rheumatoid arthritis when standard drugs fail?
Disease control Not yet recruitingThis trial is testing an experimental drug called TLL-018 in adults with moderate-to-severe rheumatoid arthritis who haven't responded well to or couldn't tolerate standard treatments. Participants will receive either TLL-018 or a placebo for a period, and the study will measure …
Phase: PHASE2 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New MS drug trial for kids: could ocrelizumab help?
Disease control Not yet recruitingThis study tests a drug called ocrelizumab in children and teens aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). The goal is to see how the drug moves through the body, if it is safe, and how it affects the immune system. Participants will receive the drug as a sh…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a single injection tame stubborn multiple sclerosis?
Disease control Not yet recruitingThis early-stage trial is testing an investigational injection called GT802 in people with relapsing or refractory multiple sclerosis (MS) — meaning their disease is active despite standard treatments. The study aims to check whether GT802 is safe and to get a first look at wheth…
Phase: EARLY_PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a targeted drug beat radiation for early-stage lymphoma?
Disease control Not yet recruitingThis phase 3 trial compares the experimental drug surovatamig with standard involved-site radiotherapy (with or without rituximab) in people with limited-stage follicular lymphoma. The goal is to see if surovatamig can produce deeper, longer-lasting responses and reduce the chanc…
Phase: PHASE3 • Sponsor: Australasian Leukaemia and Lymphoma Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new drug combo outsmart resistant lymphomas?
Disease control Not yet recruitingThis phase II trial is testing whether a combination of two targeted drugs—pirtobrutinib and sonrotoclax—can shrink tumors in people with three types of B-cell lymphoma: transformed diffuse large B-cell lymphoma, relapsed or refractory chronic lymphocytic leukemia/small lymphocyt…
Phase: PHASE2 • Sponsor: Changzhou No.2 People's Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a cancer biopsy predict who responds to a new immunotherapy?
Disease control Not yet recruitingThis phase 2 trial is testing the drug glofitamab in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Glofitamab is a type of immunotherapy that helps the body's T-cells attack cancer cells. The study uses tumor biopsies tak…
Phase: PHASE2 • Sponsor: Joshua Brody • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a single infusion tame tough lupus?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called SNC116 in people with refractory systemic lupus erythematosus (SLE), a form of lupus that hasn't improved with standard treatments. The study aims to see if a single intravenous infusion of SNC116 is safe and tolerable…
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could a common blood thinner shield psoriasis Patients' arteries?
Disease control Not yet recruitingThis trial tests whether antiplatelet medications, specifically clopidogrel and aspirin, can reduce inflammation in the blood vessels of people with psoriasis or psoriatic arthritis. Participants take each drug or a placebo for four weeks, and researchers measure changes in infla…
Phase: PHASE4 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Real-World study reveal the staying power of guselkumab?
Disease control Not yet recruitingThis observational study tracks how long patients with moderate-to-severe Crohn's disease or ulcerative colitis continue taking guselkumab, a biologic treatment, in everyday clinical practice. Researchers will measure time until treatment discontinuation and early responses like …
Sponsor: Janssen Sciences Ireland UC • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
CLL patients may get a break from daily pills
Disease control Not yet recruitingThis study looks at whether people with chronic lymphocytic leukemia (CLL) who have been in remission for at least two years can safely stop taking their BTK inhibitor medication. The goal is to see how long they stay cancer-free without treatment, and whether stopping improves t…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug combo aims to boost lymphoma treatment
Disease control Not yet recruitingThis trial tests whether adding an experimental drug called birelentinib to standard chemotherapy (R-CHOP) improves outcomes for people with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Participants receive either birelentinib plus R-CHOP or a placebo plus R-CHOP. The s…
Phase: PHASE2, PHASE3 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could a liquid diet help Crohn's patients get better faster?
Disease control Not yet recruitingThis study looks at whether adding a special liquid diet (partial enteral nutrition) to standard medication helps people with active Crohn's disease achieve remission without steroids. About 80 participants will choose to either add the diet or not. The main goal is to see if mor…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a new biologic calm the immune attack in ulcerative colitis?
Disease control Not yet recruitingThis early-stage trial is testing whether a drug called aletekitug is safe and tolerable for people with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. The drug works by blocking a protein called IL-18, which may play a role in the inflammation that …
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Head-to-Head: which JAK inhibitor wins for myelofibrosis patients with low blood counts?
Disease control Not yet recruitingThis study compares two FDA-approved drugs, momelotinib and ruxolitinib, in people with myelofibrosis who also have low blood cell counts. The main goal is to see which drug does a better job at shrinking the spleen and reducing the need for blood transfusions. About 268 particip…
Phase: PHASE4 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could a High-Protein, High-Fiber diet tame ulcerative colitis?
Disease control Not yet recruitingThis study will test whether a diet rich in protein and fiber can reduce harmful gas-producing bacteria in the gut of people with ulcerative colitis. Forty adults with mild to moderate disease will eat specially prepared frozen meals for two separate week-long periods. Researcher…
Phase: NA • Sponsor: University of Minnesota • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a new biologic tame ulcerative colitis?
Disease control Not yet recruitingThis early trial is testing an experimental biologic drug called aletekitug in adults with moderate to severe ulcerative colitis. The main goal is to see if the drug is safe and tolerable when given repeatedly. Researchers will monitor side effects and changes in lab tests, vital…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Bee glue and sound waves: new hope for diabetic wounds?
Disease control Not yet recruitingThis study tests whether using ultrasound to push propolis (a natural bee product) into the skin can help heal diabetic foot ulcers faster. Eighty adults with diabetes and foot ulcers will either get propolis plus ultrasound or standard wound care for 4 weeks. The goal is to see …
Phase: NA • Sponsor: Sinai University • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a pill tame ulcerative colitis? new trial seeks answers
Disease control Not yet recruitingThis early-stage trial is testing an experimental oral medication called Alpha-0261 in about 10 adults with moderate to severe ulcerative colitis. The main goal is to check the drug's safety and tolerability, while also looking at whether it can help reduce symptoms and lead to c…
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Anhui Medical University • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a targeted antibody tame kidney inflammation without heavy steroids?
Disease control Not yet recruitingThis phase 2 trial is testing whether a new drug called obinutuzumab beta, combined with a short course of steroids, can help people with newly diagnosed ANCA-associated glomerulonephritis—a rare autoimmune disease that causes kidney inflammation and damage. The study will enroll…
Phase: PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a new pill ease the hardening skin of systemic sclerosis?
Disease control Not yet recruitingThis phase II trial is testing an experimental tablet called TollB-001 in adults with systemic sclerosis, a rare autoimmune disease that causes skin thickening and can affect internal organs. The study aims to see whether the drug can improve skin symptoms and overall well-being …
Phase: PHASE2 • Sponsor: Toll Biotech Co. Ltd. (Beijing) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug cocktail aims to clear stubborn hand and foot pustules
Disease control Not yet recruitingThis Phase 3 trial tests whether combining two drugs, tofacitinib and imatinib, can safely clear the painful pustules of palmoplantar pustulosis (PPP), a rare chronic skin disease on the palms and soles. About 135 adults with moderate-to-severe PPP will receive either the combo o…
Phase: PHASE3 • Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat scleroderma in landmark trial
Disease control Not yet recruitingThis study tests whether a one-time infusion of specially engineered immune cells (CAR T cells) can improve lung function and skin hardening better than current treatments for people with active systemic sclerosis, a rare autoimmune disease. About 92 adults with lung involvement …
Phase: PHASE3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a pill outperform biologics for severe eczema?
Disease control Not yet recruitingThis study looks at how well upadacitinib, a daily pill, works compared to biologic injections for people with moderate-to-severe atopic dermatitis (eczema). The goal is to see if more patients can reach a state of minimal disease activity, meaning nearly clear skin and little to…
Sponsor: AbbVie • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a new pill tame psoriasis? early safety trial begins
Disease control Not yet recruitingThis early-stage trial is testing an experimental oral drug called HL40626S in healthy adults aged 18 to 55. The goal is to check the drug's safety, how the body processes it, and the best dose range. If it passes these initial safety checks, the drug could eventually be studied …
Phase: PHASE1 • Sponsor: HighsLab Therapeutics Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a simple injection replace an IV for this myeloma drug?
Disease control Not yet recruitingThis trial is testing whether belantamab, a drug used for multiple myeloma, can be given as a quick injection under the skin instead of a slow drip into a vein. About 22 adults with multiple myeloma who are already on standard maintenance therapy will receive both forms in a cros…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a dual immunotherapy erase hidden myeloma cells?
Disease control Not yet recruitingThis phase 3 trial tests whether combining two immunotherapies, teclistamab and talquetamab, can eliminate residual cancer cells in multiple myeloma patients who have undergone a stem cell transplant. Participants with detectable minimal residual disease (MRD) are randomly assign…
Phase: PHASE3 • Sponsor: Polish Myeloma Consortium • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Triple-Drug cocktail targets Hard-to-Treat blood cancers
Disease control Not yet recruitingThis phase I trial is testing whether combining three drugs—pacritinib, venetoclax, and azacitidine—is safe and tolerable for people with accelerated or blast phase myeloproliferative neoplasms, aggressive blood cancers. The study enrolls about 20 adults whose disease has progres…
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can umbilical cord stem cells help repair spinal cord injuries?
Disease control Not yet recruitingThis trial is testing whether a single injection of stem cells from umbilical cord tissue, given into the spinal fluid, is safe and tolerable for people who have had a traumatic spinal cord injury within the past ten years. The study will monitor participants for side effects and…
Phase: EARLY_PHASE1 • Sponsor: Cell Therapy LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a higher dose of upadacitinib rescue ulcerative colitis patients when standard treatment fails?
Disease control Not yet recruitingThis study tests whether a temporary higher dose of upadacitinib (45 mg daily) can bring ulcerative colitis back under control in adults whose disease flared up while on the standard 30 mg maintenance dose. Participants receive the higher dose for 8 to 16 weeks, then may step dow…
Phase: PHASE4 • Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a bispecific antibody tame two autoimmune blood disorders?
Disease control Not yet recruitingThis trial is testing an investigational drug called velinotamig in adults with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has relapsed or not responded to standard treatments. Velinotamig is an engineered bispecific antibody designed to target…
Phase: PHASE1, PHASE2 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a Three-Drug combo outsmart High-Risk CLL?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding a new immune-boosting drug, epcoritamab, to two existing targeted therapies (ibrutinib and venetoclax) can improve outcomes for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have TP53 …
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
Disease control Not yet recruitingThis phase II trial is testing whether a planned dose reduction of the targeted therapy zanubrutinib can maintain control of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) while reducing long-term side effects in patients aged 80 and older who have not yet…
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a wearable sensor outsmart diabetic ketoacidosis?
Disease control Not yet recruitingThis study looks at whether a wearable device that tracks both glucose and ketones can help people with type 1 diabetes avoid diabetic ketoacidosis (DKA), a serious complication. About 1,200 adults and children with type 1 diabetes will use the Abbott Continuous Dual Glucose Keto…
Sponsor: Abbott Diabetes Care • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a new drug ease the dryness, pain, and fatigue of Sjögren's disease?
Disease control Not yet recruitingThis phase 2 trial is testing whether an experimental drug called DDY391 can reduce disease activity and improve symptoms like dryness, pain, and fatigue in people with Sjögren's disease. About 344 participants will receive either DDY391 at one of three dose levels or a placebo f…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Dual-Pronged CAR T-Cell therapy takes aim at Hard-to-Treat leukemia
Disease control Not yet recruitingThis phase 1 trial tests a new cell therapy called KITE-753 for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. KITE-753 is made from a patient's own immune cells, which are modified to recognize and attack leuke…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a biologic drug safely tame Back-Joint inflammation? a Real-World trial investigates
Disease control Not yet recruitingThis study tracks the safety of secukinumab, a biologic injection, in Indian adults with axial spondyloarthritis — a group of inflammatory conditions that cause back pain and stiffness. Over 16 weeks, researchers will monitor side effects and disease activity in about 60 particip…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can Real-Time MRI make radiation safer for Ultra-Central lung tumors?
Disease control Not yet recruitingThis trial tests whether MRI-guided stereotactic body radiotherapy (SBRT) can safely treat ultra-central lung tumors—growths located near the windpipe and major airways. Using an MR-LINAC machine, doctors can adjust the radiation beam in real time as the patient breathes, potenti…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Personalizing leukemia care for seniors: a fitness-based treatment strategy put to the test
Disease control Not yet recruitingThis phase 2 trial tests whether using a comprehensive geriatric assessment to guide treatment selection can reduce side effects and improve outcomes in adults aged 60 and older with newly diagnosed acute myeloid leukemia. Participants are classified as fit, vulnerable, or frail,…
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a reduced-intensity drug combo tame high-risk myeloma in frail older patients?
Disease control Not yet recruitingThis trial tests whether a combination of isatuximab plus a reduced-intensity version of standard chemotherapy (VRDlite) can effectively treat newly diagnosed multiple myeloma in frail older adults who are not candidates for a stem cell transplant. The study focuses on patients w…
Phase: PHASE2, PHASE3 • Sponsor: The Affiliated People's Hospital of Ningbo University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can an online brain workout sharpen thinking in multiple sclerosis?
Disease control Not yet recruitingThis trial tests whether a year-long, home-based cognitive training program can improve memory, attention, and emotional understanding in people with multiple sclerosis. Participants use the COGWEB platform plus exercises for recognizing facial expressions, with most sessions don…
Phase: NA • Sponsor: Sonia Batista • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Gut bacteria swap may tame diabetes and thyroid disease
Disease control Not yet recruitingThis trial tests whether a one-time dose of fecal microbiota transplantation (FMT) — taking capsules containing processed donor stool — can improve blood sugar control and reduce thyroid antibodies in adults who have both type 2 diabetes and Hashimoto's thyroiditis. All 38 partic…
Phase: PHASE4 • Sponsor: Shen Xujun • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a menin inhibitor tame myelofibrosis when standard drugs fall short?
Disease control Not yet recruitingThis trial investigates whether revumenib, a menin inhibitor, can safely and effectively treat myelofibrosis, a type of bone marrow cancer. The study first tests revumenib alone in patients who have already tried a JAK inhibitor, then tests it in combination with a JAK inhibitor.…
Phase: PHASE1, PHASE2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a Two-Drug combo wipe out hidden leukemia cells?
Disease control Not yet recruitingThis phase 2 trial is testing whether combining venetoclax and zanubrutinib can drive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) into deep remission. The study enrolls adults who either have not been treated before or whose cancer returned at least two…
Phase: PHASE2 • Sponsor: Kerry Rogers • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a heart drug tame rheumatoid arthritis?
Disease control Not yet recruitingThis trial tests whether nicorandil, a drug currently used for heart conditions, can reduce disease activity and symptoms in people with rheumatoid arthritis. About 70 adults with moderate-to-severe RA will take either nicorandil or a placebo twice daily for three months, while c…
Phase: PHASE2, PHASE3 • Sponsor: Ain Shams University • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can engineered immune cells tame stubborn autoimmune diseases?
Disease control Not yet recruitingThis phase 1 trial tests an experimental cell therapy called LMY-922 (BAFF CAR-T cells) in people aged 16 to 75 with refractory autoimmune diseases, including rheumatoid arthritis, lupus, dermatomyositis, and systemic sclerosis. The therapy uses donor immune cells engineered to t…
Phase: PHASE1 • Sponsor: Luminary Therapeutics • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can two immune boosters outsmart follicular lymphoma without chemo?
Disease control Not yet recruitingThis phase II trial is testing whether combining two lab-made antibodies, tafasitamab and rituximab, can help people with newly diagnosed follicular lymphoma achieve complete remission. Both antibodies are designed to help the immune system recognize and attack cancer cells. The …
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a single cream tackle both skin and nail psoriasis?
Disease control Not yet recruitingThis trial tests whether a daily application of roflumilast 0.3% cream can improve both chronic plaque psoriasis and moderate-to-severe nail psoriasis. People aged 12 and older with stable disease for at least 6 months apply the cream to affected nails and plaques daily for 24 we…
Phase: PHASE4 • Sponsor: Modern Research Associates, PLLC • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.
Disease control Not yet recruitingThis phase 1 trial is testing an experimental drug called ATG-201 in adults with systemic lupus erythematosus, systemic sclerosis, or Sjögren's disease. ATG-201 is designed to bind to specific proteins on immune cells, potentially quieting the overactive immune response that driv…
Phase: PHASE1 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
A pre-treatment pill may supercharge cancer-fighting immune cells
Disease control Not yet recruitingThis early-phase trial tests whether giving the drug iberdomide before collecting a patient's T cells can improve the fitness of those cells for CAR-T therapy. The study enrolls adults with relapsed or refractory multiple myeloma who are already scheduled for standard CAR-T treat…
Phase: EARLY_PHASE1 • Sponsor: Shambavi Richard • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New drug combo aims to shield Children's hearts from kawasaki disease
Disease control Not yet recruitingThis study tests whether adding a drug called firsekibart to the standard treatment (IVIG and aspirin) can better prevent coronary artery damage in children with Kawasaki disease. Kawasaki disease causes inflammation in blood vessels, especially those supplying the heart, and can…
Phase: PHASE2, PHASE3 • Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a new drug combo outsmart Hard-to-Treat myeloma?
Disease control Not yet recruitingThis phase 3 trial is testing whether an experimental drug called etentamig, combined with pomalidomide, can control multiple myeloma that has come back or stopped responding to treatment. About 520 adults who have already tried 1 to 3 prior therapies will be randomly assigned to…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Ancient herbs meet modern medicine: can Curcumin-QingDai tame UC?
Disease control Not yet recruitingThis study tests whether adding a combination of curcumin (from turmeric) and QingDai (a traditional Chinese herb) to standard vedolizumab treatment can help people with moderate to severe ulcerative colitis reach remission. About 160 adults will receive either the herbal combo o…
Phase: PHASE4 • Sponsor: Ryan C Ungaro • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a pill tame Sjögren's? a new drug puts the immune system to the test
Disease control Not yet recruitingThis phase 2 trial is testing whether an oral drug called ICP-488 can reduce disease activity in people with primary Sjögren's syndrome, an autoimmune condition that causes dry eyes, dry mouth, and fatigue. About 240 adults aged 18 to 70 with moderate-to-active disease will recei…
Phase: PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a targeted pill tame a rare immune disease?
Disease control Not yet recruitingThis phase 2 trial is testing whether the experimental drug luvometinib, taken alone or with the chemotherapy drug cytarabine, can control Langerhans cell histiocytosis—a rare disease where immune cells build up and damage tissues. People aged 10 and older who need systemic treat…
Phase: PHASE2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a Two-Pronged antibody boost chemo against tough lymphomas?
Disease control Not yet recruitingThis trial tests whether adding the bispecific antibody glofitamab to standard chemoimmunotherapy can improve outcomes for people with Burkitt lymphoma or high-grade B-cell lymphoma with MYC and BCL2 rearrangements. These are fast-growing cancers that can be hard to treat. The st…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a new daily pill quiet the immune attack behind psoriasis?
Disease control Not yet recruitingThis phase 3 trial is testing an experimental daily capsule called TQH3906 in adults with moderate to severe plaque psoriasis. The drug works by blocking a key immune pathway involved in skin inflammation. Researchers are comparing TQH3906 against a placebo and an approved treatm…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could a liquid form of a Graft-Versus-Host disease drug be as effective as the pill?
Disease control Not yet recruitingThis trial compares a liquid (oral suspension) form of the drug belumosudil with the standard tablet in healthy adult men. The goal is to see if the liquid version is absorbed by the body in the same way, which could offer a more convenient option for people with chronic graft-ve…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a cancer drug reboot the immune system in chronic fatigue syndrome?
Disease control Not yet recruitingThis trial tests whether inebilizumab, an antibody that wipes out certain immune cells called B cells, can improve physical function in adults with ME/CFS that started after an infection. Participants receive three infusions over six months, and the study measures changes in mobi…
Phase: PHASE2 • Sponsor: Charite University, Berlin, Germany • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a burst of radiation make CAR t-cells fight cancer harder?
Disease control Not yet recruitingThis trial tests whether adding a small dose of total body radiation to standard CAR T-cell therapy can help the immune cells grow stronger and last longer in the body. It enrolls adults with relapsed or hard-to-treat diffuse large B-cell lymphoma or multiple myeloma who are alre…
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Experimental drug targets bone marrow failure
Disease control Not yet recruitingThis study tests an experimental drug called dibotatug (DR-01) in adults with bone marrow failure syndromes, including severe aplastic anemia. The goal is to see if the drug is safe and can improve blood cell counts. Participants receive dibotatug by IV infusion, and researchers …
Phase: PHASE1, PHASE2 • Sponsor: Dren Bio • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a new drug help when standard treatment fails for polycythemia vera?
Disease control Not yet recruitingThis trial tests whether an experimental drug called bomedemstat can help people with polycythemia vera (a condition where the body makes too many red blood cells) who did not get better with or could not tolerate the common treatment hydroxyurea. Participants will receive either…
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a cheaper copy of a leukemia drug work just as well?
Disease control Not yet recruitingThis phase 3 trial is testing whether a new drug called BLB101 works as well as the approved drug Blincyto for adults with a type of blood cancer called B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The study will compare how the drugs are …
Phase: PHASE3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a single drug calm lupus kidney disease without a cocktail of meds?
Disease control Not yet recruitingThis phase II trial tests whether obinutuzumab, a B-cell targeting antibody, can alone achieve complete kidney response in people with pure class V lupus nephritis—a form of lupus kidney disease with no approved treatments. Participants receive up to four infusions over seven mon…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could a spring-powered injector make cancer drug delivery smoother for patients and nurses?
Disease control Not yet recruitingThis trial tests whether a mechanical, spring-driven device called FreedomEDGE® can safely and effectively deliver daratumumab, a standard treatment for multiple myeloma and amyloidosis. Currently, nurses give these injections by hand, which can be physically demanding. About 100…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a community health worker program save lives in advanced HIV?
Disease control Not yet recruitingThis trial tests whether a package of support from a community health worker can help adults hospitalized with advanced HIV in Lusaka, Zambia, stay in care and survive longer. Participants are randomly assigned to receive the ARC intervention or standard care and are followed for…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new oral drug take on hard-to-treat leukaemia?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called AMX-883, taken by mouth, for people with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. The study will first test AMX-883 alone, th…
Phase: PHASE1 • Sponsor: Amphista Therapeutics Ltd • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a triple-drug combination tame AML without intensive chemo?
Disease control Not yet recruitingThis trial tests whether adding an experimental drug called CLN 049 to two standard AML drugs (azacitidine and venetoclax) is safe and tolerable for adults newly diagnosed with acute myeloid leukemia who are not candidates for intensive chemotherapy. The study will first find the…
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a menin-blocking drug outsmart stubborn leukemia?
Disease control Not yet recruitingThis trial is testing an experimental drug called S243249, which blocks a protein called menin, in people whose acute leukemia has come back or not responded to standard treatment. The study focuses on patients with specific genetic changes (KMT2A or NUP98 translocations, or NPM1…
Phase: PHASE1, PHASE2 • Sponsor: Servier • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new pill take on Hard-to-Treat leukemia?
Disease control Not yet recruitingThis early-phase trial is testing an experimental drug called S241656, taken as a tablet, in people with relapsed or refractory acute myeloid leukemia (AML) and related blood cancers. The study aims to find a safe dose and see how the drug behaves in the body, both alone and when…
Phase: PHASE1, PHASE2 • Sponsor: Servier • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a One-Two drug punch beat back Hard-to-Treat myeloma?
Disease control Not yet recruitingThis early-phase trial is testing whether combining two targeted drugs—talquetamab and belantamab mafodotin—can safely control multiple myeloma that has returned or stopped responding to prior treatments. The study enrolls adults with myeloma who have already tried at least one p…
Phase: PHASE1 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
A steroid-sparing strategy for IgG4-related disease: lenalidomide put to the test
Disease control Not yet recruitingThis phase III trial tests whether lenalidomide, an immune-modulating drug, can prevent disease flares in people with IgG4-related disease who are in remission. Participants receive either lenalidomide or a placebo for 52 weeks while tapering off steroids. The goal is to see if l…
Phase: PHASE3 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can an experimental injection clear stubborn psoriasis? a new trial aims to find out.
Disease control Not yet recruitingThis phase 2 trial tests whether the experimental drug SHR-1139 can improve skin clearance in adults with moderate to severe plaque psoriasis. About 60 participants will receive either SHR-1139 or a placebo over 52 weeks. The main goal is to see how many achieve complete skin cle…
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug combination targets rare childhood leukemia that resists standard treatment
Disease control Not yet recruitingThis trial tests whether adding the drug revumenib to standard chemotherapy (fludarabine and cytarabine) can help children and young adults with a rare form of acute myeloid leukemia (AML) that has come back or not responded to treatment. The study enrolls up to 27 participants a…
Phase: PHASE2 • Sponsor: Therapeutic Advances in Childhood Leukemia Consortium • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a Three-Drug cocktail replace chemo for follicular lymphoma?
Disease control Not yet recruitingThis phase 3 trial is testing whether a combination of three targeted drugs—orelabrutinib, obinutuzumab, and lenalidomide—can work as well as or better than standard chemotherapy for people with previously untreated follicular lymphoma. The goal is to see if this chemo-free appro…
Phase: PHASE3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can ulcerative colitis patients in remission ditch their daily pill?
Disease control Not yet recruitingThis trial asks whether adults with ulcerative colitis who are in deep remission can safely stop taking their JAK inhibitor medication (tofacitinib, upadacitinib, or filgotinib) instead of continuing daily maintenance therapy. Half of the 224 participants will stop treatment and …
Phase: PHASE4 • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
AI takes on lymphoma: personalized drug cocktail aims to outsmart cancer in older patients
Disease control Not yet recruitingThis study tests whether an artificial intelligence (AI) system can help choose the best combination of drugs for older patients newly diagnosed with large B-cell lymphoma. Participants are first treated with a standard two-drug regimen (ZR2), then those at intermediate or high r…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Engineered immune cells take aim at debilitating muscle weakness
Disease control Not yet recruitingThis early-phase trial tests a single infusion of universal STAR-T cells—engineered immune cells—in adults aged 18 to 65 with refractory generalized myasthenia gravis, a condition causing severe muscle weakness. The study aims to assess safety, tolerability, and signs of effectiv…
Phase: PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug combo aims to tame aggressive lymphoma in frail patients
Disease control Not yet recruitingThis early-phase trial is testing a two-step treatment for elderly or unfit patients with untreated diffuse large B-cell lymphoma (DLBCL). First, patients receive the immunotherapy drug epcoritamab alone, then they receive epcoritamab combined with a reduced-dose chemotherapy coc…
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could a common antibiotic boost eczema treatment?
Disease control Not yet recruitingThis trial investigates whether adding the antibiotic azithromycin to standard topical creams (betamethasone or tacrolimus) improves eczema symptoms in children aged 3 to 12 with mild to moderate atopic dermatitis. Researchers will measure changes in the Eczema Area and Severity …
Phase: PHASE4 • Sponsor: Cairo University • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Laser boost for stubborn psoriasis on hands and feet
Disease control Not yet recruitingThis study compares two treatments for palmoplantar psoriasis, a form of psoriasis affecting the palms and soles. One group receives a topical steroid cream alone, while the other receives the same cream plus a fractional CO2 laser treatment every four weeks. The goal is to see i…
Phase: PHASE4 • Sponsor: Cairo University • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New Four-Drug cocktail aims to wipe out Hard-to-Treat myeloma
Disease control Not yet recruitingThis study tests a combination of four drugs—sotoclax, carfilzomib, lenalidomide, and dexamethasone (called SonKRd)—in people newly diagnosed with multiple myeloma that has a specific genetic change called t(11;14). Participants must be healthy enough for a stem cell transplant. …
Phase: PHASE4 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New combo therapy aims to boost remission in Hard-to-Treat lymphoma
Disease control Not yet recruitingThis phase 2 trial tests whether a combination of the targeted drug glofitamab with chemotherapy (gemcitabine and oxaliplatin) can improve the effectiveness of a CAR-T cell therapy called lisocabtagene maraleucel in people with relapsed or refractory aggressive B-cell lymphomas. …
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Weekly pill cocktail aims to tame resistant blood cancers
Disease control Not yet recruitingThis phase 2 trial tests whether a once-weekly oral combination of decitabine-cedazuridine and venetoclax is safer and as effective as standard therapy for people with relapsed or refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, or high-risk myeloproliferati…
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could fewer plasma exchange sessions be just as effective for kids with brain inflammation?
Disease control Not yet recruitingThis trial tests whether plasma exchange (a blood-cleaning procedure) given every other day works as well as daily sessions for children with autoimmune encephalitis, a condition where the immune system attacks the brain. The study involves 22 children who are randomly assigned t…
Phase: NA • Sponsor: Menoufia University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New daily pill aims to tame psoriatic arthritis symptoms
Disease control Not yet recruitingThis phase 2 trial tests an experimental oral drug called CBP-0276 in adults with active psoriatic arthritis, a condition causing joint pain, swelling, and skin plaques. Participants receive either a low dose (200 mg), a high dose (800 mg), or a placebo daily for 24 weeks. The ma…
Phase: PHASE2 • Sponsor: Clarent Biopharma, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Fewer radiation sessions may be just as effective for thymic tumors after surgery
Disease control Not yet recruitingThis clinical trial is testing a shorter, more intense course of radiation therapy (called hypofractionated radiotherapy) for people who have had surgery for thymic epithelial tumors, including thymoma and thymic carcinoma. The goal is to see if this approach can keep the tumor f…
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a common herb ease rheumatoid arthritis?
Disease control Not yet recruitingThis study investigates whether ginkgo biloba extract can improve outcomes for people with moderate to severe rheumatoid arthritis who are already on standard disease-modifying drugs. Participants take ginkgo biloba for 12 weeks, and researchers measure changes in inflammation ma…
Phase: PHASE2, PHASE3 • Sponsor: Ain Shams University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can screening for social needs improve diabetes care for kids?
Disease control Not yet recruitingThis study tests a program where social workers screen families of youth with type 1 diabetes for social challenges like food insecurity, then connect them to community resources. The goal is to see if this approach is practical and acceptable, and whether it can improve diabetes…
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New biologic MK-1045 targets Hard-to-Treat blood cancers
Disease control Not yet recruitingThis phase 2 trial tests an experimental biologic called MK-1045 in people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study aims to see if MK-1045 is safe and tolerable, and how many participants respond to treatment. P…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a lower dose of radiation plus a targeted pill treat this lymphoma just as well?
Disease control Not yet recruitingThis study is for people with a slow-growing type of lymphoma called MALT lymphoma that has not spread. It compares a very low dose of radiation (4 Gy) combined with the targeted drug orelabrutinib against the standard higher dose of radiation (24 Gy). The goal is to see if the g…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Real-World study tests Once-Daily pill for ulcerative colitis in chinese adults
Disease control Not yet recruitingThis study looks at how the oral medication etrasimod works for Chinese adults with active ulcerative colitis (UC) in real-world settings. About 500 participants will take etrasimod as part of their routine care and be followed for at least 52 weeks. Researchers will track change…
Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Double-Pronged immune cells take aim at stubborn blood cancers
Disease control Not yet recruitingThis phase 1 trial tests an experimental therapy called 20-19 Tan BB06z CAR-T for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to treatment. The therapy involves taking a patient's own immune T cells, genetically modifying the…
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Friendly bacteria cream could soothe childhood eczema
Disease control Not yet recruitingThis study tests whether a probiotic ointment (containing live, friendly bacteria) can improve eczema in children aged 6 months to 15 years. The ointment is compared to a basic lotion over 28 days. Researchers measure skin redness, itching, and skin barrier function to see if the…
Phase: NA • Sponsor: BioGaia AB • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Chemotherapy-Free combo aims to tackle Hard-to-Treat lymphoma
Disease control Not yet recruitingThis phase 2 study tests a chemotherapy-free combination of two targeted drugs—polatuzumab vedotin and glofitamab—in people with diffuse large B-cell lymphoma that did not respond to or returned within a year of initial R-CHOP therapy. The drugs work by directly killing cancer ce…
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could a simpler eczema routine boost treatment success?
Disease control Not yet recruitingThis study explores whether giving people with mild-to-moderate eczema a straightforward treatment plan using only Opzelura cream helps them stick to their medication routine. Participants apply the cream twice daily until their skin clears, then as needed. Some participants also…
Phase: PHASE4 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New combo therapy aims to boost platelets in immune disorder
Disease control Not yet recruitingThis phase 3 trial tests whether adding romiplostim to standard prednisone treatment improves platelet counts in adults with previously untreated primary immune thrombocytopenia (ITP). Participants receive either romiplostim plus prednisone or prednisone alone. The study measures…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Vein repair during cancer surgery may prevent disfiguring swelling
Disease control Not yet recruitingThis trial tests whether repairing the facial vein during neck dissection can prevent lymphedema—painful swelling—in adults with head and neck cancer. Participants receive standard cancer surgery plus, if needed, immediate reconstruction of the facial vein. Researchers then compa…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo aims to outsmart Hard-to-Treat lymphoma
Disease control Not yet recruitingThis clinical trial is testing whether adding an experimental drug called HDM2005 to a standard treatment (rituximab and lenalidomide) can help people with mantle cell lymphoma whose cancer has returned or not responded to previous therapies. The study involves about 40 adults an…
Phase: PHASE1 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Herbal formula may help HIV patients whose immune systems Don't fully recover
Disease control Not yet recruitingThis study tests whether adding Qiling Yiqi tablets, a Chinese herbal medicine, to standard HIV therapy can improve immune function in people whose CD4 counts remain low despite successful viral suppression. The trial involves 240 adults with HIV who have been on antiretroviral t…
Phase: NA • Sponsor: Beijing University of Chinese Medicine • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Gene therapy aims to tame rare immune disorder
Disease control Not yet recruitingThis trial tests a new gene therapy called FOXP3-T4 for people with IPEX syndrome, a rare genetic condition that causes severe immune problems. The therapy involves taking a patient's own immune cells, modifying them in the lab to work better, and giving them back via a single in…
Phase: PHASE1, PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Herbal granules aim to revive immune system in HIV patients
Disease control Not yet recruitingThis study tests whether adding Fuyang Jiedu Granules, a traditional Chinese herbal mixture, to standard antiretroviral therapy can improve immune function in people with HIV who have persistently low CD4 counts despite viral suppression. The trial includes 240 adults aged 18–60 …
Phase: NA • Sponsor: Beijing University of Chinese Medicine • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could Two-Drug cocktails tame stubborn inflammatory bowel disease?
Disease control Not yet recruitingThis study tests whether combining risankizumab with either trosunilimab or ABBV-701 can safely reduce inflammation and improve symptoms in adults with moderately to severely active Crohn's disease or ulcerative colitis. Participants are randomly assigned to one of the combinatio…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Bispecific antibody shows promise for Hard-to-Treat lymphoma in Real-World study
Disease control Not yet recruitingThis study looks at how well a drug called glofitamab (a bispecific antibody) works for people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. Researchers are observing about 200 adults in China who are already…
Sponsor: Yanyan Liu • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
AR goggles could help surgeons spot cancer cells left behind during breast cancer surgery
Disease control Not yet recruitingThis trial tests whether special augmented-reality goggles can help surgeons find lymph nodes that may be missed during breast cancer surgery. The goggles show a fluorescent dye that collects in lymph nodes, allowing the surgeon to re-examine the area after the planned removal is…
Phase: NA • Sponsor: Ss. Cyril and Methodius University of Skopje • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New antibody drug aims to outsmart Treatment-Resistant myeloma
Disease control Not yet recruitingThis phase 2 trial tests an investigational drug called YKST02 in adults with multiple myeloma that has relapsed or stopped responding to prior treatments. YKST02 is a bispecific antibody designed to bind both myeloma cells and immune T cells, potentially helping the immune syste…
Phase: PHASE2 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Artificial intelligence could help prevent transplant complications by personalizing drug dosing
Disease control Not yet recruitingThis study aims to develop an artificial intelligence tool that helps doctors choose the right dose of cyclosporine for patients who have received a bone marrow transplant. Cyclosporine is used to prevent graft-versus-host disease, a serious complication where donor cells attack …
Sponsor: Yasmin medhat munir Mohamed • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Single-Dose gene therapy aims to reprogram immune cells against tough leukemia
Disease control Not yet recruitingThis early-phase trial tests a single injection of PID23, a gene therapy that instructs a patient's own immune cells to attack leukemia cells. It targets three markers (CD19, BCMA, and CD70) on cancer cells. The study enrolls up to 18 people aged 3 to 75 with relapsed or refracto…
Phase: EARLY_PHASE1 • Sponsor: Zhujiang Hospital • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug cocktails aim to outsmart Hard-to-Treat T-Cell lymphomas
Disease control Not yet recruitingThis early-phase trial tests two different drug combinations for people with T-cell lymphoma that has come back or not responded to prior treatment. One group receives belinostat plus azacitidine; the other receives belinostat plus pralatrexate. The goal is to find the safest dos…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Experimental drug targets Hard-to-Treat leukemia in small early trial
Disease control Not yet recruitingThis early study tests an experimental drug called zeprumetostat in people with a rare type of leukemia (T-cell large granular lymphocyte leukemia) that has not responded to or has come back after other treatments. Ten participants take the drug twice daily for two 28-day cycles.…
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Continued anifrolumab treatment studied for lupus and related diseases
Disease control Not yet recruitingThis study offers continued access to anifrolumab (Saphnelo) for people with systemic lupus erythematosus, systemic sclerosis, or myopathies who completed a prior anifrolumab trial and are still benefiting from the drug. Participants receive the same treatment as before, while re…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could a safer start to a key CLL drug be possible? new study reexamines the risk
Disease control Not yet recruitingThis study looks at people with chronic lymphocytic leukemia (CLL) who are about to start treatment with venetoclax, a targeted therapy. Doctors want to see if starting with other drugs first lowers the risk of tumor lysis syndrome, a dangerous side effect where cancer cells brea…
Phase: NA • Sponsor: Private Hospital of Confluent, France • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Triple-drug attack aims to wipe out hidden leukemia cells
Disease control Not yet recruitingThis phase 2 trial tests a combination of three drugs—nemtabrutinib, venetoclax, and obinutuzumab—as a first treatment for people with chronic lymphocytic leukemia (CLL). The goal is to see if this cocktail can reduce the disease to undetectable levels in the bone marrow and bloo…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Quarter-Sized implant could free type 1 diabetes patients from daily insulin
Disease control Not yet recruitingThis early-stage trial tests a small, soft implant that holds donor insulin-making cells (islets) and protects them from the immune system. The goal is to see if the device is safe and keeps the cells alive and working in adults with type 1 diabetes. Some participants are also on…
Phase: PHASE1 • Sponsor: Encellin • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
BiTE antibodies could unlock transplants for 'Incompatible' kidney patients
Disease control Not yet recruitingThis trial tests two BiTE drugs (blinatumomab and teclistamab) in 20 adults with end-stage kidney disease who have very high antibody levels (cPRA ≥90%) and have waited over 5 years for a transplant. The goal is to safely lower these antibodies enough to make a kidney transplant …
Phase: PHASE4 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can a smartphone app help teens tame type 1 diabetes?
Disease control Not yet recruitingThis study tests whether a mobile app that provides structured diabetes education can help adolescents with type 1 diabetes improve their blood sugar control, confidence, and self-care habits. Participants aged 10 to 19 with type 1 diabetes and an HbA1c of 7% or higher will use t…
Phase: NA • Sponsor: Shifa Tameer-e-Millat University • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn blood disorder
Disease control Not yet recruitingThis early-phase trial tests a new therapy called META 10-19 for people with autoimmune hemolytic anemia (AIHA) that has not responded to standard treatments. AIHA is a condition where the immune system mistakenly destroys red blood cells, causing anemia. META 10-19 uses a patien…
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Smart inhalers track Fasenra's asthma control over full dosing cycle
Disease control Not yet recruitingThis study tracks people with severe eosinophilic asthma who already take Fasenra (benralizumab) every 8 weeks. Participants use electronic monitors on their regular inhalers and a study-provided rescue inhaler (AirSupra) to see if asthma control stays steady throughout the dosin…
Phase: PHASE4 • Sponsor: Endeavor Health • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug cocktail aims to stop leukemia return after transplant
Disease control Not yet recruitingThis trial tests whether a combination of two drugs, lisaftoclax and azacitidine, can help prevent acute myeloid leukemia (AML) from coming back in patients who have already received a stem cell transplant and are at high risk of relapse. Participants are randomly assigned to rec…
Phase: PHASE3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Lupus drug anifrolumab tested as a simple shot
Disease control Not yet recruitingThis study tests anifrolumab, a drug for systemic lupus erythematosus (SLE), given either as a shot under the skin or through an IV. The goal is to see how the body processes the drug and check its safety. About 92 adults with lupus will take part.
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New oral drug aims to tame ulcerative colitis Flare-Ups
Disease control Not yet recruitingThis trial tests whether the oral drug ponesimod can help people with moderately to severely active ulcerative colitis achieve remission. Participants receive either ponesimod or a placebo daily for 16 weeks, with an option to continue on ponesimod for another 36 weeks. The study…
Phase: PHASE3 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Gene-Guided Chemo-Free strategy targets AL amyloidosis
Disease control Not yet recruitingThis study tests two chemotherapy-free treatments for people newly diagnosed with AL amyloidosis, a rare blood disorder. The choice of treatment depends on whether the patient has a specific genetic change called t(11;14). Those with t(11;14) receive a daily pill called sonrotocl…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug could unblock Crohn's-Related bowel narrowing without surgery
Disease control Not yet recruitingThis trial tests an experimental drug called ontunisertib in people with Crohn's disease who have developed scarred, narrowed sections in their bowel that cause pain and blockages. The goal is to see if the drug can reopen these narrowed areas, potentially reducing symptoms and t…
Phase: PHASE2 • Sponsor: Agomab Spain S.L.U. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New pill aims to tame rheumatoid arthritis inflammation
Disease control Not yet recruitingThis study tests an experimental oral drug called JAB-8263 in adults with active rheumatoid arthritis. The goal is to see if it is safe and can reduce joint inflammation and pain. Participants take the drug or a placebo every other day for 28 days. The trial is small and early-st…
Phase: PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug duo aims to outsmart resistant lymphoma
Disease control Not yet recruitingThis phase 2 study tests whether combining two oral drugs — lisaftoclax and pirtobrutinib — can shrink or control mantle cell lymphoma in adults whose cancer has stopped responding to or caused intolerance to prior BTK-targeted treatments. Participants take both pills daily until…
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for myeloma patients: could ramantamig plus daratumumab outperform standard care?
Disease control Not yet recruitingThis phase 3 trial will compare a new treatment, ramantamig plus daratumumab, against two standard drug combinations for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The study aims to see if the new combo can keep the cancer from p…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could a gut bacteria byproduct help tame fatty liver in type 1 diabetes?
Disease control Not yet recruitingThis trial investigates whether a supplement called butyrate (a substance produced by gut bacteria) and an intensive lifestyle program (Mediterranean diet plus exercise) can reduce liver fat in adults with type 1 diabetes who also have fatty liver disease. Participants are random…
Phase: NA • Sponsor: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New pill targets immune signals in rare lymphomas
Disease control Not yet recruitingThis pilot study tests an oral drug called golidocitinib in people with two rare blood cancers: mycosis fungoides/Sézary syndrome (a type of skin lymphoma) and T-cell large granular lymphocytic leukemia. The drug blocks a protein called JAK1, which is involved in cancer cell grow…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Cancer drug repurposed to calm brain inflammation in autoimmune disease
Disease control Not yet recruitingThis study tests whether a low dose of blinatumomab, a drug originally used for leukemia, can help people with severe autoimmune encephalitis or cerebellitis that hasn't responded to standard treatments. The drug targets and depletes certain immune cells (B cells) that are mistak…
Phase: PHASE4 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma
Disease control Not yet recruitingThis study tests a new treatment called AZD4045, which uses specially engineered immune cells (CAR-T cells) to target and kill multiple myeloma cells. The therapy is given alone or combined with other drugs (daratumumab and aldesleukin) in adults whose myeloma has returned or sto…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Two-Drug sequence aims to clear CLL cells and let patients stop treatment
Disease control Not yet recruitingThis phase 2 trial tests a treatment plan for people with newly diagnosed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants first take zanubrutinib alone for 12 cycles, then add sonrotoclax for another 12 cycles. The goal is to see if this seque…
Phase: PHASE2 • Sponsor: Yi Shuhua • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Cream-and-Steroid combo aims to recolor vitiligo patches
Disease control Not yet recruitingThis study tests whether a cream containing ruxolitinib (Opzelura) combined with corticosteroid injections or pills can improve facial vitiligo. It includes people aged 12 and older with active, non-segmental vitiligo affecting the face. Participants use the cream twice daily and…
Sponsor: ShanShan Li • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Targeted combo aims at tough lymphoma subtype
Disease control Not yet recruitingThis phase 2 trial tests whether adding the targeted drug orelabrutinib to standard chemotherapy improves outcomes for people with a specific genetic subtype of diffuse large B-cell lymphoma (MCD subtype). Participants receive the drug combination during initial treatment, follow…
Phase: PHASE2 • Sponsor: Ou Bai, MD/PHD • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
One pill may tame both itchy skin and stubborn liver disease
Disease control Not yet recruitingThis study tests whether upadacitinib, a drug already approved for eczema, can help people who have both atopic dermatitis (a type of eczema) with moderate to severe itching and a hard-to-treat autoimmune liver disease called cholangitis. The drug works by blocking a pathway invo…
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat T-Cell cancers
Disease control Not yet recruitingThis study tests a new treatment called nano CD5-CAR T cells for people with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoma. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that carry the CD5 pro…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Herbal mix and cancer drug join forces to fight fluid in lungs
Disease control Not yet recruitingThis study tests whether adding a Chinese herbal formula (Xuanyin Ning) to a standard cancer drug (bevacizumab) can better control malignant pleural effusion—fluid buildup in the chest caused by advanced lung cancer. About 308 participants will receive either the herbal formula o…
Phase: NA • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn blood cancers
Disease control Not yet recruitingThis phase 1 trial is testing a new kind of CAR-T cell therapy, called LMY-922, for people with certain blood cancers that have not responded to standard treatments. The therapy uses donor immune cells engineered to target a protein called BAFF on cancer cells. The study aims to …
Phase: PHASE1 • Sponsor: Luminary Therapeutics • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New oral pill H021 aims to tame Crohn's Flare-Ups
Disease control Not yet recruitingThis phase 2 trial tests whether an experimental oral tablet called H021 can help people with moderate to severe Crohn's disease. Participants receive either a low or high dose of H021 or a placebo for 12 weeks, with an option to continue treatment. The study measures symptom imp…
Phase: PHASE2 • Sponsor: Jiangsu Carephar Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take aim at autoimmune diseases
Disease control Not yet recruitingThis early-stage study is testing a new treatment called C-CAR168 for people with autoimmune diseases like multiple sclerosis, lupus, and myasthenia gravis that have not improved with standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab…
Phase: PHASE1 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
Disease control Not yet recruitingThis trial tests whether adding low-dose total body irradiation (TBI) to standard chemotherapy before CAR T-cell therapy (tisagenlecleucel) is safe and effective for adults with large B-cell lymphoma that has returned or not responded to prior treatments. The study involves 18 pa…
Phase: PHASE1 • Sponsor: Nathan Denlinger • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Off-the-Shelf immune cells take aim at Hard-to-Treat leukemia
Disease control Not yet recruitingThis early-phase trial is testing an experimental therapy called GT737 for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. GT737 uses specially engineered immune cells (iNKT cells) that are made in large batches and can be given…
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Triple-Drug cocktail aims to tame untreated CLL
Disease control Not yet recruitingThis phase 2 trial is testing whether a combination of three drugs—zanubrutinib, sonrotoclax, and obinutuzumab—can safely control chronic lymphocytic leukemia (CLL) in people who have not yet received treatment. About 40 participants will receive all three drugs orally. The main …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Three-Drug cocktail aims to tame transplant complications in blood cancer patients
Disease control Not yet recruitingThis trial investigates whether adding bortezomib and sitagliptin to standard post-transplant cyclophosphamide can prevent graft-versus-host disease (GvHD) in adults with blood cancers receiving a stem cell transplant. Participants receive the drug combination after transplant, w…
Phase: PHASE1, PHASE2 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take aim at childhood autoimmune diseases
Disease control Not yet recruitingThis early-phase trial tests a single infusion of universal CAR-T cells (RD06-05) in 30 children and adolescents with severe autoimmune diseases, including lupus, scleroderma, and kidney inflammation. The cells are designed to target and calm overactive immune cells. The main goa…
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a drug calm the immune storm in severe abdominal infections?
Disease control Not yet recruitingThis study tests whether ulinastatin, a drug that reduces inflammation, can help patients with severe abdominal infections. The infection often causes the immune system to overreact, leading to organ failure and high risk of death. Researchers will give patients either a low or h…
Phase: NA • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can intense breathing training boost lung power and ease fatigue in MS?
Disease control Not yet recruitingThis study tests whether high-intensity breathing exercises can improve respiratory muscle strength, lung function, fatigue, and quality of life in people with multiple sclerosis (MS). Participants are randomly assigned to high-intensity interval breathing training, low-intensity…
Phase: NA • Sponsor: Istanbul University - Cerrahpasa • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental CAR T-Cell therapy targets tough lymphoma
Disease control Not yet recruitingThis early-phase trial tests a new type of immune cell therapy called GoFast CD19 CAR T-cells in 9 adults with relapsed or refractory large B-cell lymphoma. Participants receive chemotherapy followed by an infusion of their own modified immune cells. The study aims to see if the …
Phase: EARLY_PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could a cholesterol drug and antioxidant help treat a rare bleeding disorder?
Disease control Not yet recruitingThis trial investigates whether combining atorvastatin (a cholesterol-lowering drug), N-acetyl-L-cysteine (an antioxidant), and romiplostim (a platelet-boosting drug) can help adults with immune thrombocytopenia (ITP) who no longer respond to steroids. The goal is to see if this …
Phase: NA • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Crohn's blockage showdown: drugs or surgery for better quality of life?
Disease control Not yet recruitingThis trial compares two approaches for people with Crohn's disease who have a narrowed section of the small bowel causing symptoms. One group receives a combination of two drugs (azathioprine and infliximab), while the other group undergoes surgery to remove the narrowed segment.…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to tame liver side effects of cancer immunotherapy
Disease control Not yet recruitingThis study tests whether combining mycophenolate mofetil (MMF) with prednisone can better treat liver inflammation caused by checkpoint inhibitor cancer drugs. The trial includes adults with moderate to severe immune-related hepatitis who need to pause their cancer therapy. The m…
Phase: PHASE2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New trial combines HIV PrEP and STI prevention in one package for young men
Disease control Not yet recruitingThis study tests whether a combined approach—offering HIV PrEP (pills or injections) and STI prevention (doxycycline after sex) along with smartphone tools—helps young men at high risk stay protected. About 400 men aged 18-29 who have sex with men will be followed for a year to s…
Phase: PHASE3 • Sponsor: HIV Prevention Trials Network • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New daily pill aims to tackle Hard-to-Treat lymphoma
Disease control Not yet recruitingThis study tests an experimental daily pill called HP-002 in people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. It includes several ly…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Helioson Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Not yet recruitingThis trial tests a one-time treatment called CAR-T cell therapy for people with systemic lupus erythematosus (lupus) that hasn't improved with standard medications. The therapy uses a patient's own immune cells, which are modified in a lab to find and destroy the B cells that dri…
Phase: PHASE1, PHASE2 • Sponsor: University of Sao Paulo • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Selective cell removal may tame stem cell Transplant's dangerous side effect
Disease control Not yet recruitingThis study tests whether removing a specific type of immune cell (naive T cells) from a donor's stem cell graft can prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the recipient's body. The trial enrolls people with non-malignant blood di…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental drug aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests an experimental drug called STR-P005 in people with autoimmune diseases that have come back or not improved with standard treatments. The drug is given through an IV in multiple doses. The main goal is to check safety and see how the body handles the drug. …
Phase: NA • Sponsor: Starna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
AI-Powered tool aims to sharpen MS treatment choices
Disease control Not yet recruitingThis study tests a computer program called PRIMUS that helps neurologists choose treatments for people with relapsing-remitting multiple sclerosis (MS). The tool uses data from past patients to predict how the disease might progress under different therapies. Doctors in some clin…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Automated radiation could make stem cell transplants safer for blood cancer patients
Disease control Not yet recruitingThis trial tests a new automated radiation method that precisely targets bone marrow and lymph nodes before a stem cell transplant. The goal is to kill cancer cells while reducing damage to healthy tissues. Participants have high-risk myeloid cancers like acute myeloid leukemia o…
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug cocktail targets deadliest blood cancers
Disease control Not yet recruitingThis trial investigates whether adding selinisole to standard chemotherapy drugs (azacitidine and venetoclax) can improve outcomes for people with newly diagnosed, high-risk myeloid tumors that have a TP53 mutation. These tumors are aggressive and hard to treat. The study will me…
Phase: NA • Sponsor: Bing Han • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Expired allergy tests: a hidden goldmine or a diagnostic risk?
Diagnosis Not yet recruitingThis study tests whether expired patch test allergens can still accurately diagnose allergic contact dermatitis, a common skin condition. Adults referred for patch testing will receive both expired and non-expired allergens on their skin at the same time. The researchers will com…
Phase: PHASE4 • Sponsor: University of Calgary • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
A simple blood test may reveal kidney damage in lupus — no biopsy needed?
Diagnosis Not yet recruitingThis study asks whether levels of uromodulin, a protein in the blood, can indicate the severity of kidney damage in people with lupus nephritis. Researchers will compare uromodulin levels with kidney biopsy results from 90 participants, including those with different classes of l…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
A simple blood test for lupus kidney damage?
Diagnosis Not yet recruitingThis study investigates whether levels of a protein called RNASE1 in the blood can serve as a biomarker for lupus nephritis, a serious kidney complication of systemic lupus erythematosus (SLE). Researchers will compare RNASE1 levels in 128 adults with SLE, some with lupus nephrit…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
New blood marker duo could spot leukemia earlier
Diagnosis Not yet recruitingThis study investigates whether measuring two proteins, CD38 and CD56, on white blood cells called neutrophils can help diagnose chronic myeloid leukemia (CML). Researchers will compare the levels of these markers in 200 people with CML to see if a high percentage is a reliable s…
Sponsor: Sohag University • Aim: Diagnosis
Last updated Aug 07, 2026 00:00 UTC
-
Can a tiny implant track glucose, ketones, and lactate in diabetes?
Diagnosis Not yet recruitingThis trial is testing a new implantable sensor called the HALO System in people with type 1 or type 2 diabetes. The sensor is designed to continuously measure glucose, ketones, and lactate in the fluid just beneath the skin, which could give a more complete picture of metabolic h…
Phase: NA • Sponsor: Indigo Diabetes NV • Aim: Diagnosis
Last updated Aug 06, 2026 00:00 UTC
-
A 5-Day genetic test could slash time to transplant for children with rare immune disease
Diagnosis Not yet recruitingThis trial tests whether a new ultra-rapid genetic test, using third-generation sequencing, can diagnose familial lymphohistiocytosis (FHL) in children within 5 days instead of the usual 6-8 weeks. FHL is a rare, life-threatening genetic condition where the immune system attacks …
Phase: NA • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Stool test duo could revolutionize cancer surveillance in colitis
Diagnosis Not yet recruitingThis study tests whether combining two stool tests—fecal immunochemical test (FIT) and fecal calprotectin (FC)—can accurately detect precancerous or cancerous changes in people with long-standing ulcerative colitis. Participants will provide stool samples and then undergo a speci…
Sponsor: Qilu Hospital of Shandong University • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
A mobile x-ray van with AI could spot TB before it spreads
Diagnosis Not yet recruitingThis study tests a community-based screening strategy for tuberculosis (TB) in migrant communities in New York City. A mobile van offers digital chest X-rays with AI interpretation, along with TB symptom checks, blood tests for latent TB, and HIV testing. The goal is to see wheth…
Phase: NA • Sponsor: Columbia University • Aim: Diagnosis
Last updated Aug 01, 2026 00:00 UTC
-
Ultrasound may uncover hidden arthritis in IBD patients
Diagnosis Not yet recruitingThis study tests whether combining two screening questionnaires with a musculoskeletal ultrasound can detect spondyloarthritis—a type of inflammatory arthritis—in people who already have inflammatory bowel disease (IBD) but have not been diagnosed with arthritis. Two hundred adul…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
Blood traps may reveal lupus kidney treatment success
Diagnosis Not yet recruitingLupus nephritis is a serious kidney complication of lupus that can lead to kidney failure. This study investigates whether levels of neutrophil extracellular traps (NETs)—web-like structures released by immune cells—in the blood can predict how well patients respond to therapy. R…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
Blood test plus symptom check may spare thousands from celiac biopsy
Diagnosis Not yet recruitingThis study aims to see if a blood test for TTG-IgA antibodies combined with symptom information can accurately sort adults into low, intermediate, or high risk for celiac disease. Researchers will analyze data from 15,500 patients who already had both a blood test and a duodenal …
Sponsor: The Cleveland Clinic • Aim: Diagnosis
Last updated Jul 22, 2026 00:00 UTC
-
New imaging tracer could spot hidden cancers and fibrosis in one scan
Diagnosis Not yet recruitingThis study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …
Phase: PHASE1, PHASE2 • Sponsor: Martin Huellner • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
Special formula may help diagnose milk allergy vs intolerance in infants
Diagnosis Not yet recruitingThis study tests whether a partially digested whey formula can help doctors tell the difference between a non-allergic milk intolerance and a true cow's milk protein allergy in babies. Infants aged 1 to 6 months with digestive symptoms will receive the special formula. The goal i…
Phase: NA • Sponsor: Ain Shams University • Aim: Diagnosis
Last updated Jul 09, 2026 00:00 UTC
-
Simple blood test could spot hidden myeloma years early
Diagnosis Not yet recruitingThis study tests a new blood test that looks for DNA fragments in the blood (called cfDNA) to detect multiple myeloma and its early forms (MGUS and smoldering myeloma) in people over 40. The test uses machine learning to tell the difference between healthy individuals and those w…
Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC
-
AR goggles could help surgeons spot cancer in lymph nodes in real time
Diagnosis Not yet recruitingThis study tests whether augmented-reality goggles, combined with a special dye called indocyanine green (ICG), can accurately identify cancerous lymph nodes during breast cancer surgery. Two hundred adults with breast cancer will take part. The goggles use near-infrared light to…
Sponsor: Ss. Cyril and Methodius University of Skopje • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC
-
New PET tracer aims to reveal hidden myeloma spots
Diagnosis Not yet recruitingThis study tests a new radioactive tracer for PET/CT scans that targets a protein called GPRC5D found on multiple myeloma cells. About 50 adults with plasma cell disorders, including multiple myeloma, will receive the tracer and then undergo imaging. The goal is to see if this me…
Phase: PHASE1 • Sponsor: Peking University First Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
New scan spots hidden organ damage before symptoms start
Diagnosis Not yet recruitingThis study explores whether a PET/MR scan using a radioactive tracer called 18F-Florbetaben can detect amyloid deposits—abnormal protein clumps that can damage organs—in people with certain blood disorders. Participants receive a single injection of the tracer followed by a whole…
Phase: NA • Sponsor: University of Zurich • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Olive oil as a shield? trial tests whether a daily spoonful cuts heart risks in HIV
Prevention Not yet recruitingThis trial asks whether taking 50 mL of extra virgin olive oil every day can reduce the chance of heart attacks, strokes, and related deaths in people living with HIV. About 1,300 adults aged 50–75 with well-controlled HIV and at least one heart risk factor will be randomly assig…
Phase: NA • Sponsor: Fundacion SEIMC-GESIDA • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Don't wash that baby! study tests if keeping vernix on prevents eczema
Prevention Not yet recruitingThis study tests whether leaving the white, creamy coating (vernix caseosa) on a newborn's skin for at least 24 hours after birth can prevent eczema (atopic dermatitis) during the first year of life. Over 1,300 mother-infant pairs in Chile will be randomly assigned to either keep…
Phase: NA • Sponsor: Pontificia Universidad Catolica de Chile • Aim: Prevention
Last updated Aug 13, 2026 00:00 UTC
-
Could one antibiotic dose before tooth pulling prevent infections in Immune-Weakened patients?
Prevention Not yet recruitingThis study tests whether a single dose of amoxicillin before a simple tooth extraction can prevent infections in people with autoimmune rheumatic diseases who are on immune-suppressing medications. Researchers will compare infection rates between those who get the antibiotic and …
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Yearly TB check may shield vulnerable patients from a hidden threat
Prevention Not yet recruitingThis trial investigates whether annual re-screening for tuberculosis infection using a blood test (IGRA) can prevent active TB in people with autoimmune rheumatic diseases who are taking biologic or immunosuppressive medications. Participants who initially test negative for TB ar…
Phase: NA • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 02, 2026 00:00 UTC
-
A simple survey may curb teen drinking and HIV risk — a trial puts it to the test
Prevention Not yet recruitingThis trial tests whether giving students accurate information about their peers' actual behavior can reduce heavy drinking and risky sexual activity. About 1,350 adolescents in three Ugandan schools will complete surveys and receive personalized feedback comparing their own estim…
Phase: NA • Sponsor: Vanderbilt University • Aim: Prevention
Last updated Jul 30, 2026 00:00 UTC
-
Could an arthritis drug stop type 1 diabetes before it starts?
Prevention Not yet recruitingThis trial tests whether golimumab, a drug used for arthritis, can delay or prevent type 1 diabetes in people who have early signs of the disease but normal blood sugar. Participants receive monthly injections of golimumab or a placebo for up to 6 years. The study tracks how long…
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
Can a common antipsychotic keep cannabis users out of the ER?
Symptom relief Not yet recruitingThis trial tests whether giving patients a prescription for haloperidol to use as needed at home can help control symptoms of cannabinoid hyperemesis syndrome — a condition marked by severe nausea, vomiting, and abdominal pain from heavy cannabis use. The goal is to see if having…
Phase: EARLY_PHASE1 • Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Aug 18, 2026 02:00 UTC
-
Can a specialized hand exercise protocol restore grip and ease pain in rheumatoid arthritis?
Symptom relief Not yet recruitingThis trial tests whether a new hand rehabilitation program, called SMART-HAND, can improve hand function, joint position sense, pain, and dexterity in people with rheumatoid arthritis. The program combines sensory training, massage, joint approximation, range-of-motion exercises,…
Phase: NA • Sponsor: Istanbul University - Cerrahpasa • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Learning to Self-Care: a new approach to ease RA stiffness?
Symptom relief Not yet recruitingThis trial tests whether a structured self-care education program can reduce joint stiffness and improve functional ability in people with rheumatoid arthritis. Participants are split into two groups: one receives the education program alongside usual care, while the other gets u…
Phase: NA • Sponsor: Assiut University • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Can Brain-Training apps fix sleep in MS?
Symptom relief Not yet recruitingThis study tests whether AI-based cognitive training, using the Lumosity app, combined with a tailored physical-therapy program can improve sleep and quality of life in people with multiple sclerosis. Participants aged 25-40 with mild to moderate disability will undergo the train…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
New app aims to prevent dangerous blood sugar dips during workouts for type 1 diabetes
Symptom relief Not yet recruitingThis pilot study tests a software tool called NEXT that gives personalized advice on insulin and carbohydrate adjustments before and after exercise for adults with type 1 diabetes. Twenty participants will try three different approaches to managing their blood sugar around exerci…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Can an inhaled powder calm the painful Cold-Finger attacks of scleroderma?
Symptom relief Not yet recruitingThis study tests an inhaled powder called LIQ861 (treprostinil) in adults with scleroderma who have frequent, painful Raynaud's attacks—episodes where fingers or toes turn color and become numb or tingly. About 75 participants will be randomly assigned to receive either a dose th…
Phase: PHASE2 • Sponsor: Liquidia Technologies, Inc. • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Mind over MS: could online therapy lift the fog of depression?
Symptom relief Not yet recruitingThis study tests whether an online mindfulness-based cognitive therapy (MBCT) program can reduce depression in people with multiple sclerosis (MS) who also have mild to moderate depression. The program involves live group sessions over eight weeks. Researchers will compare change…
Phase: PHASE3 • Sponsor: Robert Simpson • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Mind over ache: could meditation tame MS pain?
Symptom relief Not yet recruitingThis trial tests whether a structured mindfulness program can reduce pain in adults with multiple sclerosis. Participants are randomly assigned to either the mindfulness group or an educational program, and their pain, fatigue, sleep, mood, and quality of life are tracked over se…
Phase: NA • Sponsor: Hospital Universitario Virgen Macarena • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Zapping pain without drugs: brain stimulation put to the test for nerve pain
Symptom relief Not yet recruitingThis trial tests whether a non-invasive brain stimulation technique called temporal interference stimulation (tTIS) can reduce neuropathic pain—pain caused by nerve damage. Researchers will monitor changes in pain levels and brain plasticity in 60 adults with peripheral neuropath…
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Art as medicine: can drawing and painting help sick kids feel better about themselves?
Symptom relief Not yet recruitingThis trial tests whether a structured art therapy program, grounded in positive psychology, can improve self-compassion and hope in children aged 8 to 12 who are staying in a hospital ward. Half of the 80 participants will receive the art therapy sessions alongside standard nursi…
Phase: NA • Sponsor: Suleyman Demirel University • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Can meditation tame the Long-Term side effects of a stem cell transplant?
Symptom relief Not yet recruitingThis trial tests whether a mindfulness-based stress reduction program — including group sessions and one-on-one coaching — can help people living with chronic graft-versus-host disease (cGVHD) manage symptoms like pain, anxiety, and poor sleep. cGVHD is a complication that can oc…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Could a 16-Week home exercise program change the course of early MS?
Symptom relief Not yet recruitingThis trial tests whether a 16-week remote physical activity program, including online newsletters and video coaching, can improve motivation and behavior in people newly diagnosed with multiple sclerosis (within the last 2 years). Participants will wear a Fitbit and log steps whi…
Phase: NA • Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Could a common anesthetic ease severe asthma in kids?
Symptom relief Not yet recruitingThis Phase 2 trial tests whether inhaled ketamine can improve breathing in children aged 1 to 13 with severe asthma attacks that do not respond to standard treatments. Participants receive either nebulized ketamine or a placebo every six hours for 24 hours, alongside usual care. …
Phase: PHASE2 • Sponsor: Sultan Qaboos University • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
Can a new rowing seat help veterans with paralysis row freely?
Symptom relief Not yet recruitingThis trial compares two adaptive indoor rowing seats designed for Veterans who have limited trunk stability due to spinal cord injury, stroke, or neurodegenerative conditions. Participants will try both seats during short rowing sessions, and researchers will measure trunk moveme…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
Pedaling away swelling: could cycling boost leg lymphedema treatment?
Symptom relief Not yet recruitingThis trial tests whether adding aerobic exercise (cycling on a recumbent bike) to standard complete decongestive therapy can improve muscle thickness, balance, mobility, and quality of life in adults with lower extremity lymphedema. Participants will exercise 20–30 minutes per se…
Phase: NA • Sponsor: Bursa Yuksek Ihtisas Training and Research Hospital • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
A motorized hip brace may help MS patients walk better — small study puts it to the test
Symptom relief Not yet recruitingThis study tests whether a powered hip-flexion device called Hypershell X can immediately improve walking in people with multiple sclerosis who have hip weakness. Ten participants will walk short distances with the device set to different levels of assistance. Researchers will me…
Phase: NA • Sponsor: University of Dayton • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Sleep hormone melatonin put to the test against lupus fatigue and inflammation
Symptom relief Not yet recruitingThis trial investigates whether taking melatonin before bed can improve sleep quality, reduce fatigue, and lower inflammation in adults with active lupus. Sixty-four participants will either receive standard care plus melatonin or standard care alone for 12 weeks. Researchers wil…
Phase: PHASE2, PHASE3 • Sponsor: Ain Shams University • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Could a wearable nerve stimulator help MS patients walk more freely?
Symptom relief Not yet recruitingThis trial tests a wearable device that uses mild electrical pulses to stimulate the leg muscles of people with multiple sclerosis who have foot drop. The goal is to see if using the device for several months improves walking quality, physical activity, and participation in daily…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jul 24, 2026 00:00 UTC
-
Home workouts may rev up muscle energy in lupus patients
Symptom relief Not yet recruitingThis study tests whether a 16-week personalized home exercise program can improve muscle health and reduce fatigue in adults with stable lupus. Participants do three weekly sessions combining high-intensity interval training, strength exercises, and walking. Researchers measure c…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Brain training without drugs: can imagining movement ease MS pain?
Symptom relief Not yet recruitingThis study tests two types of brain training—motor imagery (mentally picturing movements) and sensorimotor training (repetitive sensory exercises)—against standard therapy for people with multiple sclerosis who have neuropathic pain in their legs. The goal is to see which approac…
Phase: NA • Sponsor: Uludag University • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
New allergy pill could offer relief from sneezing and stuffy nose
Symptom relief Not yet recruitingThis study tests an experimental antihistamine called rupatifen fumarate for people with seasonal allergic rhinitis (hay fever). About 550 adults aged 18 to 65 with at least a 2-year history of seasonal allergies will take either the new drug, an existing antihistamine, or a plac…
Phase: PHASE3 • Sponsor: Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
Could a squeeze of acid make gum Dark-Spot removal look better?
Symptom relief Not yet recruitingThis study tests whether applying citric acid during a procedure to remove dark gum pigmentation leads to better-looking results and faster healing. Adults aged 18 to 50 with natural dark gums will receive either standard depigmentation or depigmentation plus acid. The researcher…
Phase: NA • Sponsor: Dijlah University • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Digital Self-Care could ease lymphatic pain after breast cancer
Symptom relief Not yet recruitingThis study tests a digital behavioral program called The-Optimal-Lymph-Flow (TOLF Self-Care) for breast cancer survivors who experience lymphatic pain—a common, often painful condition that can lead to chronic lymphedema. The program teaches self-care skills to promote lymph flow…
Phase: NA • Sponsor: University of Missouri, Kansas City • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
Finger injections aim to loosen stiff hands in scleroderma
Symptom relief Not yet recruitingThis early-phase trial investigates whether monthly injections of hyaluronidase into the fingers can improve stiffness and hand function in people with systemic sclerosis who have sclerodactyly (tight, thickened skin on the fingers). The study enrolls 10 adults aged 18 to 60 and …
Phase: EARLY_PHASE1 • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Could weekly yoga ease fatigue and pain in autoimmune disease?
Symptom relief Not yet recruitingThis study looks at whether a 12-session weekly yoga program, added to usual medical care, can help adults with systemic autoimmune and inflammatory diseases (like lupus) feel less tired, have less pain, and improve their mood. Researchers will also check if yoga helps people sti…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
Could a simple supplement boost knee injection results for arthritis sufferers?
Symptom relief Not yet recruitingThis study tests whether adding an oral supplement (PEA) to a series of knee injections (adelmidrol and hyaluronic acid) can better reduce pain and improve function in people with knee arthritis. The injections aim to protect the joint from damage, while the supplement may help c…
Phase: NA • Sponsor: Universita di Verona • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
New injection could tame teen hay fever
Symptom relief Not yet recruitingThis study tests whether an injection called stapokibart can reduce nasal allergy symptoms like runny nose, congestion, sneezing, and itching in adolescents aged 12 to 17 with seasonal allergic rhinitis (hay fever). Participants receive either stapokibart or a placebo alongside t…
Phase: PHASE3 • Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
AI coach for parents of diabetic kids: will it make carb counting easier?
Symptom relief Not yet recruitingThis study tests whether an AI-powered educational platform can help parents of children with type 1 diabetes count carbohydrates more accurately and manage diabetes better. About 80 parents will either use the AI platform plus usual care or usual care alone for 12 weeks. The goa…
Phase: NA • Sponsor: Sultan Qaboos University • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Hypnosis as a hospital treatment for gut disorders?
Symptom relief Not yet recruitingThis pilot study compares recorded gut-directed hypnosis to an educational recording for hospitalized patients with chronic gut problems, such as irritable bowel syndrome or inflammatory bowel disease. Participants listen to the recordings over the phone while in the hospital for…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Can a 2-Hour online class ease IBD pain?
Symptom relief Not yet recruitingThis study tests two online pain education programs for adults with Crohn's disease or ulcerative colitis who have chronic pain. Participants will complete a 2-hour online session and report their pain and quality of life weekly for 8 weeks. The goal is to see if these programs a…
Phase: NA • Sponsor: Cedars-Sinai Medical Center • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Can a phone app help RA patients feel less anxious?
Symptom relief Not yet recruitingThis study tests whether an 8-week program of yoga and meditation delivered through a mobile app can reduce anxiety in adults with stable rheumatoid arthritis. About 100 participants will either use the app daily or continue with standard care. Researchers will measure changes in…
Phase: NA • Sponsor: Tugba Civi Karaaslan • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Could a bone drug ease pain in kids with rare inflammatory disease?
Symptom relief Not yet recruitingThis study tests whether the drug zoledronate can reduce pain in children aged 4 to 17 with chronic recurrent multifocal osteomyelitis (CRMO), a rare auto-inflammatory bone disease. The 30 participants have not responded to standard anti-inflammatory drugs. They will receive eith…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Can a smartphone app ease the Gut-Brain struggle for IBD patients?
Symptom relief Not yet recruitingThis study tests a mobile app designed to help Black and Hispanic adults with inflammatory bowel disease (IBD) manage stress and improve their quality of life. The app teaches coping skills, mindfulness, and disease acceptance. Researchers want to see if the app is practical and …
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Toolkits may unlock better diabetes support for teens
Knowledge-focused Not yet recruitingThis study tests whether structured toolkits—including staff education, referral plans, and billing guidance—can help pediatric diabetes clinics deliver a behavioral intervention called Diabetes Coaching to more families of teens with type 1 diabetes. Researchers will ask whether…
Phase: NA • Sponsor: Nemours Children's Clinic • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Scientists launch deep dive into IBD to uncover hidden clues
Knowledge-focused Not yet recruitingThis study will follow 100 adults with Crohn's disease, ulcerative colitis, or other IBD, plus their healthy relatives, for up to 3 years. Researchers will collect blood, stool, tissue samples, and imaging to track how immune cells and genetics change over time. The goal is to fi…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Blood tests could reveal who benefits from Next-Gen lymphoma antibodies
Knowledge-focused Not yet recruitingThis observational study is looking at whether biological markers in blood, tumor tissue, and imaging scans can predict how well patients with B-cell non-Hodgkin lymphoma respond to treatment with novel monoclonal antibodies. Researchers will collect samples from about 1,000 adul…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Wireless glucose sensors could transform ICU care — but can they deliver?
Knowledge-focused Not yet recruitingThis study tests whether continuous glucose monitors (CGMs) like the Dexcom G7 can be safely and effectively used in intensive care units. The monitors provide real-time blood sugar readings and alarms for dangerously high or low levels, potentially reducing the need for frequent…
Sponsor: Imperial College Healthcare NHS Trust • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Could you help scientists unlock genetic cancer secrets?
Knowledge-focused Not yet recruitingThis study screens up to 1,000 people with personal or family histories of certain cancers to see if they qualify for ongoing genetics research at the National Cancer Institute. Participants fill out a 15-20 minute online survey about their health and family history. No treatment…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Blood's tiny messengers may expose hidden brain injury
Knowledge-focused Not yet recruitingThis study investigates whether tiny particles called extracellular vesicles, released by brain cells into the blood, can serve as reliable markers of nerve damage in people with multiple sclerosis or stroke. Researchers will measure these particles in blood samples from 60 parti…
Sponsor: Roberto Furlan • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Can we decode the different types of pain in multiple sclerosis?
Knowledge-focused Not yet recruitingThis study aims to classify the different types of chronic pain experienced by people with multiple sclerosis (MS). Researchers will use a detailed clinical assessment to categorize pain as nociceptive, neuropathic, nociplastic, or mixed. The goal is to see if different pain type…
Sponsor: Kutahya Health Sciences University • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can a Life-Saving transplant leave hidden scars on a Child's mind?
Knowledge-focused Not yet recruitingThis study looks at children aged 6 to 8 who had a stem cell transplant at least two years ago to treat a primary immunodeficiency—a genetic condition that weakens the immune system. Researchers will use standardized tests and interviews to measure the children's thinking skills,…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can 3D-Printed models unlock personalized blood cancer therapies?
Knowledge-focused Not yet recruitingThis study aims to create 3D models of B-cell cancers—like chronic lymphocytic leukemia, splenic marginal-zone lymphoma, and hairy cell leukemia—using blood samples from patients. The goal is to build realistic models that mimic the tumor environment, which could help researchers…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Hidden MS progression: can brain scans and blood tests predict it?
Knowledge-focused Not yet recruitingThis study follows 180 people with early relapsing-remitting multiple sclerosis (MS) to understand why some experience disability progression even without relapses. Researchers will use MRI scans, eye tests, and blood biomarkers to see if they can predict this type of progression…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New study tracks hidden dangers of common leukemia drug
Knowledge-focused Not yet recruitingThis study will follow 200 children with acute lymphoblastic leukemia or lymphoma to learn more about the short- and long-term side effects of asparaginase drugs. Researchers will track how often serious toxicities occur during standard treatment and a newer therapy called SJALL2…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can a skin biopsy reveal how axatilimab fights scarring in chronic GVHD?
Knowledge-focused Not yet recruitingThis study investigates how axatilimab, an FDA-approved drug for chronic graft-versus-host disease (cGVHD), changes immune cells in the skin. Researchers will analyze skin and blood samples from 15 adults with skin cGVHD—10 starting axatilimab and 5 not receiving it—to understand…
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can a smart tool keep watch on leukemia after treatment stops?
Knowledge-focused Not yet recruitingThis study explores whether a digital tool can help monitor adults with chronic myeloid leukemia who have stopped treatment for up to two years. Over 12 months, researchers will track how often patients use the tool, aiming for a usage rate of at least 60%. The goal is to see if …
Phase: NA • Sponsor: Versailles Hospital • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can biological signals explain mastocytosis symptoms?
Knowledge-focused Not yet recruitingThis study aims to understand how symptoms of indolent systemic mastocytosis relate to biological signals in the body. Researchers will collect samples and data from 25 participants over 12 weeks to see how different treatments affect these signals. The goal is to improve underst…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Immune clues in the blood may foretell heart trouble
Knowledge-focused Not yet recruitingThis study is building a biobank of blood samples and imaging data from 300 people with suspected inflammatory heart or autoimmune rheumatic diseases. Researchers aim to identify immune biomarkers that could predict major heart events like heart failure, stroke, or atrial fibrill…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
A simple blood draw could spare kids with leukemia from painful bone marrow tests
Knowledge-focused Not yet recruitingThis study looks at whether a blood test that detects tumor DNA (ctDNA) can give the same information as bone marrow tests in children with acute leukemia. Researchers will compare ctDNA results with standard bone marrow checks for minimal residual disease. The goal is to see if …
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
New hope for rare blood disorder: study reviews real-world use of enzyme therapy
Knowledge-focused Not yet recruitingThis study looks back at medical records of people with congenital thrombotic thrombocytopenic purpura (cTTP), a rare inherited blood disorder that causes dangerous blood clots. Participants received a manufactured version of the missing ADAMTS13 enzyme through an early access pr…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Could a simple protein test unlock the secrets of joint disease?
Knowledge-focused Not yet recruitingThis study looks at whether levels of a protein called 15-PGDH in the blood and joint fluid are linked to the severity of osteoarthritis and ankylosing spondylitis. Researchers will measure 15-PGDH in about 51 adults with these conditions and compare it with ultrasound images and…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Could a single injection tame the immune system in lupus?
Knowledge-focused Not yet recruitingThis early-stage trial is testing a single injection of an experimental drug called SHR-7012 in healthy adults. The main goal is to check how safe and tolerable the drug is, and how the body absorbs and processes it. The study involves about 50 participants aged 18 to 55, who wil…
Phase: PHASE1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Could a simple skin test replace bone marrow biopsies?
Knowledge-focused Not yet recruitingThis study explores whether a non-invasive, painless skin measurement called electrical bioimpedance can help monitor acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). About 25 adults who are already scheduled for a bone marrow biopsy will also receive this skin te…
Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Hidden liver risk in type 1 diabetes: a new study investigates
Knowledge-focused Not yet recruitingThis study looks at how common fatty liver disease (MASLD) is in adults with type 1 diabetes. Researchers will check 250 adults with type 1 diabetes for signs of liver fat and scarring, using non-invasive tests. The goal is to understand if type 1 diabetes raises the risk of live…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Engineering immune cells to outsmart Leukemia's defenses
Knowledge-focused Not yet recruitingThis study investigates how to engineer T cells to more effectively target acute myeloid leukemia (AML). Researchers will analyze samples from healthy donors and AML patients to identify T-cell receptors that recognize leukemia cells. The goal is to create next-generation enginee…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can an app help older leukemia patients track their health at home?
Knowledge-focused Not yet recruitingThis pilot study tests whether adults aged 65 and older with acute leukemia can use a digital platform to complete health questionnaires from home. Twenty participants will fill out surveys about their quality of life and symptoms on a tablet or phone, with results sent directly …
Phase: NA • Sponsor: Fundación para la Investigación Biosanitaria del Principado de Asturias • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can your phone's camera measure psoriasis redness as well as a doctor?
Knowledge-focused Not yet recruitingThis study aims to develop and test an AI system that uses smartphone photos with a color card to measure redness in psoriasis lesions. Fifty adults with psoriasis will take weekly photos at home and have clinic photos taken. The goal is to see if this simple, low-cost method mat…
Sponsor: Khon Kaen University • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Can a prefilled pen match a syringe for this biosimilar?
Knowledge-focused Not yet recruitingThis study compares two ways of giving the same experimental biosimilar drug, DRL_AB, which is designed to work like abatacept for autoimmune conditions. Healthy male volunteers receive a single dose either through an autoinjector or a prefilled syringe. Researchers measure how m…
Phase: PHASE1 • Sponsor: Dr. Reddy's Laboratories Limited • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
AI vs. human: which doctor video boosts psoriasis treatment adherence?
Knowledge-focused Not yet recruitingThis study explores whether short, AI-generated videos from a virtual doctor can help people with psoriasis stick to their topical medication routine. Fifteen adults will be split into three groups: weekly AI videos, weekly human doctor videos, or standard care (one follow-up vis…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Could a protein blocker quiet Leukemia's alarm system?
Knowledge-focused Not yet recruitingThis study investigates whether blocking a protein called IRAK4 can disrupt TLR signaling in leukemia cells from people with chronic lymphocytic leukemia (CLL). Researchers will collect extra blood samples from 50 adults with CLL during routine blood tests. In the lab, they will …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
MRI scans may reveal hidden clues to myeloma relapse risk
Knowledge-focused Not yet recruitingThis study is looking at whether a special type of whole-body MRI can help predict how well people with multiple myeloma will do after a stem cell transplant. The MRI measures changes in bone marrow and fat content in the bones, which might indicate if the cancer is more likely t…
Sponsor: Fondazione EMN Italy Onlus • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
New HIV prevention drug faces drug interaction test
Knowledge-focused Not yet recruitingThis early-stage study looks at how a common tuberculosis drug, rifampin, affects levels of a new HIV prevention medicine called MK-8527. Fourteen adults with latent TB (no active symptoms) will take MK-8527 with and without rifampin. The goal is to see if the two drugs can be us…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Rewiring the immune system: a new hope for children with severe IBD?
Knowledge-focused Not yet recruitingThis study investigates why children with inflammatory bowel disease (IBD) have an overactive immune response in the gut, and whether blood stem cells can be engineered to restore tolerance. Researchers will analyze blood and intestinal tissue samples from 80 children with IBD, w…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Does CAR-T therapy affect the brain? a study investigates
Knowledge-focused Not yet recruitingThis study follows people with relapsed or refractory multiple myeloma who are scheduled to receive BCMA CAR-T therapy, a type of cell treatment. Researchers will test memory, attention, and other thinking skills at the start and again at 1, 6, and 12 months after the infusion. T…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
A simple Note-Taking change could transform blood cancer care
Knowledge-focused Not yet recruitingThis quality improvement initiative tests whether a standardized electronic medical record template for progress notes, combined with a pharmacist-led medication titration service, can improve the management of polycythemia vera (PV). The study enrolls hematologists and oncologis…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
A swallowable spy pill could unlock Sjögren's secrets
Knowledge-focused Not yet recruitingThis study uses a novel ingestible mini-pill to collect bacteria samples from different parts of the gut in people with Sjögren's disease and healthy volunteers. By comparing these samples with mouth and stool bacteria, researchers hope to understand how the microbiome relates to…
Phase: NA • Sponsor: Tufts University • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Personalized dosing may improve stem cell transplant survival in blood cancer patients
Knowledge-focused Not yet recruitingThis study compares survival and other outcomes in patients with acute leukemia or myelodysplastic syndrome who received a stem cell transplant with a personalized dose of an immune-suppressing drug (r-ATG) to similar patients from a large registry who received standard treatment…
Sponsor: Miltenyi Biomedicine GmbH • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Can mapping fish allergy profiles in kids improve diagnosis?
Knowledge-focused Not yet recruitingThis study follows 120 children and adolescents in Spain who have been newly diagnosed with IgE-mediated fish allergy. Researchers will collect data on symptoms, test results, and molecular sensitization patterns to better understand how fish allergy presents in this population. …
Sponsor: Carmelo Escudero • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Disposable scope takes on gold standard in pleural diagnosis
Knowledge-focused Not yet recruitingThis pilot trial tests whether a single-use flexible bronchoscope can safely and effectively replace the semi-rigid pleuroscope for diagnosing pleural effusion—a buildup of fluid around the lungs. Hospitalized patients needing a tissue sample will be randomly assigned to one of t…
Phase: NA • Sponsor: National University of Malaysia • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Virtual bees and wasps may alter allergy immune responses — a trial puts it to the test
Knowledge-focused Not yet recruitingThis study tests whether immersive virtual reality (VR) exposure to bees or wasps can influence immune, brain, and body responses in adults with venom allergy. Participants will experience a realistic VR picnic scene where virtual insects approach and simulate a sting, while rese…
Phase: NA • Sponsor: University of Geneva, Switzerland • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Could a daily walk shield the brain's wiring in aging MS patients?
Knowledge-focused Not yet recruitingThis study investigates whether physical activity and other lifestyle factors are linked to changes in myelin—the protective coating around nerve fibers—in people aged 50 to 70 who have had multiple sclerosis for over a decade. Participants will undergo MRI scans to measure myeli…
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
A simple blood marker may reveal hidden heart risks in lupus
Knowledge-focused Not yet recruitingThis study investigates whether the triglyceride-glucose (TyG) index, a simple blood-based measure of insulin resistance, can predict early signs of atherosclerosis in people with lupus nephritis. Researchers will measure carotid artery thickness and plaque in 156 adults with lup…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Amniotic cell secretions may fight gut inflammation and scarring — a lab study puts them to the test
Knowledge-focused Not yet recruitingThis lab study tests whether a cell-free mixture of molecules and particles released by human amniotic mesenchymal stromal cells can reduce inflammation, prevent scarring, and promote healing in gut tissue from people with inflammatory bowel disease (Crohn's disease or ulcerative…
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Ultrasound and blood markers may unlock personalized treatment for rare nerve disease
Knowledge-focused Not yet recruitingThis study investigates whether nerve ultrasound patterns and biomarkers in blood and spinal fluid can predict how people with chronic inflammatory demyelinating polyneuropathy (CIDP) respond to treatment. Researchers will follow 30 adults with CIDP, including newly diagnosed and…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Can better detection of precancerous lesions in IBD prevent colorectal cancer?
Knowledge-focused Not yet recruitingPeople with inflammatory bowel disease (Crohn's disease or ulcerative colitis) have a higher risk of developing colorectal cancer. This study follows 800 adults with IBD who need a screening colonoscopy to look for precancerous growths called dysplasia. Researchers aim to underst…
Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Blood particles may reveal hidden clues to scleroderma complications
Knowledge-focused Not yet recruitingThis study looks at how tiny particles called extracellular vesicles travel through the bloodstream in people with systemic sclerosis, an autoimmune disease that affects blood vessels and organs. Researchers will take blood samples from different points in the circulation to see …
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma
Knowledge-focused Not yet recruitingThis study aims to enroll 10,000 adults across the United States to help identify genetic variants linked to blood cancers such as leukemia, lymphoma, and myeloma. Participants complete online health surveys and provide a saliva sample by mail. Researchers will analyze the DNA to…
Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
CAR-T breakthroughs come with infection risks – new study aims to decode them
Knowledge-focused Not yet recruitingThis study follows adults with multiple myeloma or B-cell lymphoma who receive CAR-T cell therapy, a powerful immune treatment. Researchers track infections that occur in the first year after treatment, looking at how common they are, what causes them, and which factors raise the…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Smartwatches track hidden heart risk in blood cancer patients
Knowledge-focused Not yet recruitingThis study investigates how often atrial fibrillation (AF), a type of irregular heartbeat, occurs in people with certain blood cancers who are starting a targeted cancer drug called a Bruton's tyrosine kinase inhibitor (BTKI). Researchers will follow 500 participants—400 starting…
Sponsor: Tina Baykaner • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Does the setting of care affect whether kids finish their antibiotics?
Knowledge-focused Not yet recruitingThis observational study looks at whether children aged 3 months to 16 years are more likely to complete their full course of antibiotics when prescribed at a primary care clinic versus a hospital emergency department. Researchers surveyed parents by phone after treatment ended t…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Digital tests may offer a new way to track brain health in tumor patients
Knowledge-focused Not yet recruitingThis study explores whether self-administered digital cognitive tests can accurately measure thinking skills like attention, memory, and processing speed in people with primary central nervous system lymphoma or low-grade gliomas. Participants will complete both digital tests (on…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Allergy study seeks to pinpoint those most bothered by cats and birch pollen
Knowledge-focused Not yet recruitingThis study aims to identify and describe people with allergic conjunctivitis (eye allergies) caused by cats or birch tree pollen, with or without accompanying allergic rhinitis (hay fever). Researchers will collect information and perform allergy tests to see who qualifies for fu…
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Could a simple blood test predict lupus in children with ITP?
Knowledge-focused Not yet recruitingThis study looks at children with immune thrombocytopenic purpura (ITP) who also have certain antibodies, as they are at higher risk of developing lupus. Researchers will analyze blood samples to track immune cell changes and markers that may signal the transition to lupus. The g…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Could early markers unlock treatments for a rare childhood disease?
Knowledge-focused Not yet recruitingThis study follows babies and young children (up to age 5) who have a genetic diagnosis of ataxia telangiectasia (A-T), a rare disease that affects movement and immunity. Researchers use brain and lung scans, blood tests, and movement analysis to spot early signs of disease progr…
Sponsor: University of Nottingham • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Skin disease evolution under the microscope: a 17-Year look at what drives severity
Knowledge-focused Not yet recruitingThis study follows 5,000 people with common inflammatory skin conditions—like eczema, psoriasis, and hidradenitis suppurativa—over up to 17 years to see how their disease severity changes. Researchers will collect medical history, treatments, and symptom scores to identify factor…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Genetic clues may forecast multiple sclerosis after vision loss
Knowledge-focused Not yet recruitingThis observational study looks at whether combining genetic information with standard clinical data can better predict who will develop multiple sclerosis after a first episode of optic neuritis (inflammation of the optic nerve). Researchers will follow 180 people aged 16 and old…
Sponsor: King's College London • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Newborn SCID screening study aims to unlock secrets of immune disorders
Knowledge-focused Not yet recruitingThis study follows infants who had a positive newborn screening test for severe combined immunodeficiency (SCID), a group of genetic disorders that leave babies vulnerable to life-threatening infections. Researchers will track these children to identify the underlying causes of t…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Blood fats and nanoparticles may reveal hidden clues in autoimmune liver disease
Knowledge-focused Not yet recruitingThis study looks at two types of liver disease — autoimmune hepatitis and non-alcoholic fatty liver disease — to see if fats in blood cells and tiny particles called extracellular vesicles differ between them. Researchers will collect blood samples from 24 adults and analyze thes…
Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Scientists target GLUT1 to tame immune attacks in type 1 diabetes
Knowledge-focused Not yet recruitingThis study investigates whether blocking GLUT1, a protein that helps immune cells use sugar, can reduce the autoimmune attack that destroys insulin-producing cells in type 1 diabetes. Researchers will analyze stored blood samples from adults with type 1 diabetes and test immune c…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
CT scans track hip implant movement to predict Long-Term stability
Knowledge-focused Not yet recruitingThis study tracks 30 people receiving a CATALYSTEM cementless hip implant to measure how much the stem moves (subsides) in the thigh bone over two years. Using specialized CT scans, researchers aim to see if the implant stays firmly in place, which is key for long-term success. P…
Phase: NA • Sponsor: Canadian Radiostereometric Analysis Network • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
New oral drug for eczema takes first step in human safety trial
Knowledge-focused Not yet recruitingThis early-stage study tests the safety and tolerability of an experimental oral drug called HRS-8797 in healthy volunteers aged 18 to 55. Researchers will also measure how the drug behaves in the body and whether food affects its absorption. The goal is to gather essential safet…
Phase: PHASE1 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
HIV and cancer: study seeks to uncover hidden risk factors
Knowledge-focused Not yet recruitingThis study looks at how certain cancers develop in people with HIV and what factors might increase their risk. Researchers will analyze medical data from 1,000 HIV-positive adults to track which types of cancer occur most often and why. The goal is to improve early detection and …
Sponsor: Shenzhen Third People's Hospital • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Migrant HIV study: does social status shape treatment success?
Knowledge-focused Not yet recruitingThis study looks at how a person's migration history and social situation affect how well HIV treatment works. Researchers will compare the health outcomes of 150 migrants living with HIV in France, based on their social and administrative status. The goal is to understand whethe…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Blood test may end painful bone marrow biopsies for myeloma patients
Knowledge-focused Not yet recruitingThis study tests whether a blood test using mass spectrometry can detect minimal residual disease (tiny amounts of cancer left after treatment) in multiple myeloma patients. Currently, doctors must take bone marrow samples, which is painful and inconvenient. The blood test would …
Sponsor: Odense University Hospital • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Smartwatch data could help predict cancer outcomes
Knowledge-focused Not yet recruitingThis study collects health data from Apple Watches and iPhones of 1,200 cancer patients to build a research database. The goal is to see if wearable data like activity and heart rate can help personalize cancer prognosis and treatment. Participants must have an Apple Health app a…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
New glucose monitor aims for pinpoint accuracy in diabetes care
Knowledge-focused Not yet recruitingThis pilot study tests a new continuous glucose monitor (CGM) called SAVA in 20 adults with Type 1 Diabetes. Participants wear three SAVA sensors and one standard sensor for 15 days to check how well the SAVA measures blood sugar compared to lab tests. The study also looks at com…
Phase: NA • Sponsor: SAVA Technologies Ltd. • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Dutch hospital data reveals hidden patterns in IBD treatment
Knowledge-focused Not yet recruitingThis study looks at medical records from thousands of adults with Crohn's disease or ulcerative colitis treated in Dutch hospitals between 2018 and 2026. Researchers will analyze which treatments patients receive, how often they switch therapies, and how the disease affects other…
Sponsor: LOGEX • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Acupuncture points may signal hidden disease activity
Knowledge-focused Not yet recruitingThis study investigates whether acupuncture points become tender or more sensitive in people with inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis. Researchers will compare skin temperature, blood flow, and pain sensitivity at specific body points b…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Could poor balance be the hidden link between MS fatigue and fear of falling?
Knowledge-focused Not yet recruitingThis study investigates whether balance problems explain why fatigue leads to a greater fear of falling in people with multiple sclerosis (MS). Researchers will assess fatigue, balance, and fear of falling in 40 adults with MS who can walk independently or with a device. The goal…
Sponsor: Uskudar University • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Hidden toll of myasthenia gravis: study probes sexual and bladder problems often overlooked
Knowledge-focused Not yet recruitingThis study investigates sexual and urinary problems in people with generalized myasthenia gravis, an autoimmune disease that causes muscle weakness. While visible symptoms like droopy eyelids are well-known, issues like sexual dysfunction and bladder problems are often ignored. R…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Genetic clue may unlock why lupus hits some people harder
Knowledge-focused Not yet recruitingThis study investigates whether a specific gene variation (ICOS) is linked to developing systemic lupus erythematosus (SLE) and how severe the disease becomes. Researchers will analyze blood samples from 30 people diagnosed with SLE to look for patterns in the ICOS gene. The goal…
Sponsor: South Valley University • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Will a new drug form work the same? study tests two versions of SKI-O-703
Knowledge-focused Not yet recruitingThis study tests whether two different capsule forms of the experimental drug SKI-O-703 are absorbed similarly in the body. About 48 healthy adults (Korean and Caucasian) will take a single dose of each form on separate days, with blood samples taken to compare drug levels. The r…
Phase: PHASE1 • Sponsor: Oscotec Inc. • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Home devices may spot lung flare-ups before they become emergencies
Knowledge-focused Not yet recruitingThis study tests whether people with fibrotic interstitial lung disease can use home monitoring devices—like a spirometer, pulse oximeter, and scale—to help detect serious lung events such as flare-ups or hospitalizations. About 200 participants will use these devices connected t…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Could HIV treatment choice affect sleep? new study investigates
Knowledge-focused Not yet recruitingThis study looks at sleep health in people with HIV who are on different antiretroviral therapies. Some participants switch from a dolutegravir-based regimen to a doravirine-based one, while others stay on dolutegravir. Sleep is measured using questionnaires, wrist-worn activity …
Phase: PHASE4 • Sponsor: University of Witwatersrand, South Africa • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Smartwatches may spot IBD flares before symptoms start
Knowledge-focused Not yet recruitingThis study explores whether changes in heart rate, sleep, and activity measured by a person's own smartwatch can predict flare-ups in inflammatory bowel disease (IBD). Six hundred adults with Crohn's disease or ulcerative colitis who already own a compatible device will participa…
Sponsor: Maastricht University Medical Center • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Radioactive tracer reveals how potential Crohn's drug moves through the body
Knowledge-focused Not yet recruitingThis trial in 8 healthy men aged 30–65 examines how the body absorbs, breaks down, and eliminates ontunisertib, an experimental oral drug for fibrostenotic Crohn's disease. Participants receive a single dose of the drug with a radioactive label, allowing researchers to track its …
Phase: PHASE1 • Sponsor: Agomab Spain S.L.U. • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Baby blood test could predict type 1 diabetes risk
Knowledge-focused Not yet recruitingThis study aims to identify newborns with a high genetic risk of developing type 1 diabetes. Researchers will screen 50,000 infants using a simple genetic test to find those with a greater than 10% risk. The goal is not to treat diabetes, but to find eligible babies for future pr…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New ultrasound aims to spot twin pregnancy complications before they start
Knowledge-focused Not yet recruitingThis study will test a new, high-speed ultrasound device on 10 healthy women pregnant with identical twins who share a placenta. The goal is to see if the device can take detailed pictures of the tiny blood vessels in the placenta. This information could help doctors better under…
Phase: NA • Sponsor: Carilion Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New foot scanner aims to help diabetics spot problems early
Knowledge-focused Not yet recruitingThis pilot study will test how easy it is for 20 adults with diabetes to set up and use the Feetsee foot monitoring device at home over 8 weeks. Participants will use the device and app on their own, following the instructions provided. The goal is to see if people can use it cor…
Sponsor: Diabetis JSC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Can AI predict heart trouble in IBD patients?
Knowledge-focused Not yet recruitingThis study looks at people with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, to better understand their risk of serious heart problems like stroke and heart attack. Researchers will collect information on therapy, disease activity, lifestyle…
Sponsor: IRCCS Policlinico S. Donato • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Simple CT scan could reveal hidden heart risks in HIV patients
Knowledge-focused Not yet recruitingThis study investigates whether a simple coronary CT scan can detect early signs of heart disease in people with HIV. Researchers will measure calcium buildup in the heart arteries of 384 Mexican adults with HIV who have undetectable viral loads. The goal is to better understand …
Sponsor: Instituto Mexicano del Seguro Social • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Could cousins be as good as siblings for stem cell donation?
Knowledge-focused Not yet recruitingThis study looks at whether using a cousin as a stem cell donor works as well as using a sibling for people with blood cancers. Researchers will compare survival, relapse, and side effects like graft-versus-host disease in patients who received a transplant from either a cousin o…
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Brain fog after lymphoma: study probes lasting cognitive effects of chemotherapy
Knowledge-focused Not yet recruitingThis study looks at thinking skills, memory, and quality of life in people who are 3 to 5 years past successful treatment for Hodgkin lymphoma or certain types of B-cell lymphoma. Participants take a series of tests and questionnaires once during a regular follow-up visit. The go…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists map the genetic secrets of a rare brain cancer to pave the way for smarter treatments
Knowledge-focused Not yet recruitingThis study examines tumor samples from 100 people diagnosed with primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL), a rare cancer that starts in the brain or spine. Researchers will use advanced genetic and molecular techniques to identify patterns in the …
Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC